

Curriculum Vitae

Professor

Division of Hematology
Department of Molecular Biotechnology and Health Sciences
Università degli Studi di Torino
Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino
via Genova 3, 10126 Torino
Tel (011) 6335878



Education:

Medical Degree, University of Torino, 1975
Postgraduate degree in Hematology, University of Bologna, 1978
Postgraduate degree in Internal Medicine, University of Torino, 1983

Professional records:

- Post-doctoral fellow, Free University of Brussels, Molecular Biology Department, Brussels, 1978
- Assistant Professor, Department of Medicine and Experimental Oncology, University of Torino, 1980
- Visiting Investigator, Arizona Cancer Center, Section of Hematology, Jun-Sep 1982, Feb-Nov 1983
- Associate Professor, Department of Medicine and Experimental Oncology, University of Torino, 1982
- Coordinator of the Italian Multiple Myeloma Study Group for the M83 national trial comparing two different
 - conventional chemotherapy regimens
- Professor of Hematology, Department of Medicine and Experimental Oncology, University of Torino, 1990
- Coordinator of the Postgraduate degree in Hematology, University of Torino, 1990-present
- Coordinator of the Italian Multiple Myeloma Study Group for the M90 national trial comparing two different
 - conventional chemotherapy regimens
- Coordinator of the Italian group of the European Research Network supported by the European Community, 1991-1996
- Coordinator of the Italian Multiple Myeloma Study Group for the M97G national trial comparing an intensified chemotherapy regimen with peripheral blood progenitor cell support versus conventional chemotherapy
- Director of the University Haematology Section of the Oncology Department, Jan 2000 – present

Professional Societies:

Società Italiana di Ematologia (SIE)
Società Italiana di Ematologia Sperimentale (SIES)
European Hematology Association (EHA)
American Society of Hematology (ASH)
American Society of Clinical Oncology (ASCO)

Current Grant Support:

National Research Center (CNR), Italy
Italian Research Cancer Association (AIRC), Italy,
University of Torino
CNR, Progetto Ponte
MURST
Fondazione San Paolo di Torino

Scientific Interests:

Multiple Myeloma
- efficacy of high-dose versus conventional chemotherapy
- role of prognostic factors
- immunosurveillance and immunotherapy
- molecular alterations and minimal residual disease

Publications:

439 contributions on international peer-reviewed journals; H-Index 77
(Oct 2019; source: Scopus – <https://www.scopus.com/>)

Clinical Trial Experience:

Experience in studies of phase I, II, III concerning Multiple Myeloma

ICH-GCP Training:

ICH-CGP training attended for previous clinical trials

GCP certification validated by TransCelerate on November 21, 2016

GCP certification (E6 – R2) validated by TransCelerate on October 16, 2017

I authorize the processing of my personal data pursuant to art. 13 of Legislative Decree 30 June 2003, n. 196 "Code regarding the protection of personal data" and art. 13 of the GDPR (EU Regulation 2016/679).

Torino, October 22nd, 2019

Mario Boccadoro



Publications – Full-text articles

- Musto, P., Simeon, V., Cascavilla, N., Falcone, A., Petrucci, M. T., Cesini, L., ... Corso, A. (2019). Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study). *Annals of Hematology*, 98(2), 361–367. <https://doi.org/10.1007/s00277-018-3524-1>
- Saltarella, I., Morabito, F., Giuliani, N., Terragna, C., Omedè, P., Palumbo, A., ... Ria, R. (2019). Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial. *Journal of Hematology and Oncology*, 12(1). <https://doi.org/10.1186/s13045-018-0691-4>
- Coscia, M., Vitale, C., Cerrano, M., Maffini, E., Giaccone, L., Boccadoro, M., & Bruno, B. (2019). Adoptive immunotherapy with CAR modified T cells in cancer: Current landscape and future perspectives. *Frontiers in Bioscience - Landmark*, 24(7), 1284–1315. <https://doi.org/10.2741/4780>
- Cerrano, M., Candoni, A., Crisà, E., Dubbini, M. V., D'Ardia, S., Zannier, M. E., ... Ferrero, D. (2019). FLAI induction regimen in elderly patients with acute myeloid leukemia. *Leukemia and Lymphoma*. <https://doi.org/10.1080/10428194.2019.1620943>
- Costello, C., Davies, F. E., Cook, G., Vela-Ojeda, J., Omel, J., Rifkin, R. M., ... Hungria, V. (2019). INSIGHT MM: A large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. *Future Oncology*, 15(13), 1411–1428. <https://doi.org/10.2217/fon-2019-0013>
- Ludwig, H., Bokemeyer, C., Aapro, M., Boccadoro, M., Gascón, P., Denhaerynck, K., ... Macdonald, K. (2019). Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study. *Future Oncology*, 15(8), 897–907. <https://doi.org/10.2217/fon-2018-0814>
- Bringhen, S., Mina, R., Petrucci, M. T., Gaidano, G., Ballanti, S., Musto, P., ... Larocca, A. (2019). Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: A pooled analysis of two phase i/ii studies. *Haematologica*, 104(8), 1640–1647. <https://doi.org/10.3324/haematol.2018.208272>
- Ludwig, H., Gascón, P., Bokemeyer, C., Aapro, M., Boccadoro, M., Denhaerynck, K., ... Abraham, I. (2019). Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated “same-day” (< 24 h), “per-guidelines” (24–72 h), and “late” (> 72 h): findings from the MONITOR-GCSF study. *Supportive Care in Cancer*, 27(6), 2301–2312. <https://doi.org/10.1007/s00520-018-4513-6>
- Bringhen, S., Milan, A., D'Agostino, M., Ferri, C., Wäsch, R., Gay, F., ... Engelhardt, M. (2019). Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. *Journal of Internal Medicine*, 286(1), 63–74. <https://doi.org/10.1111/joim.12882>
- Gambella, M., Omedé, P., Spada, S., Muccio, V. E., Gilestro, M., Saraci, E., ... Oliva, S. (2019). Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis. *Cancer*, 125(5), 750–760. <https://doi.org/10.1002/cncr.31854>
- Plesner, T., Arkenau, H.-T., Gay, F., Minnema, M. C., Boccadoro, M., Moreau, P., ... Richardson, P. G. (2019). Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study. *British Journal of Haematology*, 186(3), e35–e39. <https://doi.org/10.1111/bjh.15879>
- Offidani, M., Boccadoro, M., Di Raimondo, F., Petrucci, M. T., Tosi, P., & Cavo, M. (2019). Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma. *Current Hematologic Malignancy Reports*, 14(3), 187–196. <https://doi.org/10.1007/s11899-019-00507-x>
- Giaccone, L., Evangelista, A., Patriarca, F., Sorasio, R., Pini, M., Carnevale-Schianca, F., ... Bruno, B. (2018). Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple

- Myeloma. *Biology of Blood and Marrow Transplantation*, 24(1), 189–193. <https://doi.org/10.1016/j.bbmt.2017.09.017>
- Muccio, V. E., Saraci, E., Gilestro, M., Oddolo, D., Ruggeri, M., Caltagirone, S., ... Omedè, P. (2018). Relevance of sample preparation for flow cytometry. *International Journal of Laboratory Hematology*, 40(2), 152–158. <https://doi.org/10.1111/ijlh.12755>
- Ghione, P., Genuardi, E., Rossi, D., Drandi, D., Mantoan, B., Barbero, D., ... Ferrero, S. (2018). Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow-up. *British Journal of Haematology*, 181(5), 693–695. <https://doi.org/10.1111/bjh.14681>
- Drandi, D., Genuardi, E., Dogliotti, I., Ferrante, M., Jiménez, C., Guerrini, F., ... Ferrero, S. (2018). Highly sensitive MYD88 ^{1265p} mutation detection by droplet digital polymerase chain reaction in waldenström macroglobulinemia. *Haematologica*, 103(6), 1029–1037. <https://doi.org/10.3324/haematol.2017.186528>
- Salvini, M., Troia, R., Giudice, D., Pautasso, C., Boccadoro, M., & Larocca, A. (2018). Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma. *Expert Opinion on Drug Metabolism and Toxicology*, 14(1), 91–99. <https://doi.org/10.1080/17425255.2018.1417388>
- Lia, G., Brunello, L., Bruno, S., Carpanetto, A., Omedè, P., Festuccia, M., ... Bruno, B. (2018). Extracellular vesicles as potential biomarkers of acute graft-vs-host disease. *Leukemia*, 32(3), 765–773. <https://doi.org/10.1038/leu.2017.277>
- Agnelli Giacchello, J., Valeri, F., Boccadoro, M., & Borchiellini, A. (2018). Thrombopoietin receptor agonists in patients with persistent or chronic immune thrombocytopenia. *European Journal of Haematology*, 100(3), 304–307. <https://doi.org/10.1111/ejh.13014>
- Gay, F., Engelhardt, M., Terpos, E., Wäsch, R., Giaccone, L., Auner, H. W., ... Sonneveld, P. (2018). From transplant to novel cellular therapies in multiple myeloma: European myeloma network guidelines and future perspectives. *Haematologica*, 103(2), 197–211. <https://doi.org/10.3324/haematol.2017.174573>
- Bringhen, S., D'Agostino, M., De Paoli, L., Montefusco, V., Liberati, A. M., Galieni, P., ... Boccadoro, M. (2018). Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. *Leukemia*, 32(4), 979–985. <https://doi.org/10.1038/leu.2017.327>
- Bringhen, S., Mina, R., Cafro, A. M., Liberati, A. M., Spada, S., Belotti, A., ... Boccadoro, M. (2018). Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. *Leukemia*, 32(8), 1803–1807. <https://doi.org/10.1038/s41375-018-0024-1>
- Larocca, A., Dold, S. M., Zweegman, S., Terpos, E., Wäsch, R., D'Agostino, M., ... Engelhardt, M. (2018). Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). *Leukemia*, 32(8), 1697–1712. <https://doi.org/10.1038/s41375-018-0142-9>
- Cetani, G., Boccadoro, M., & Oliva, S. (2018). A look at treatment strategies for relapsed multiple myeloma. *Expert Review of Anticancer Therapy*, 18(8), 735–750. <https://doi.org/10.1080/14737140.2018.1477594>
- Efficace, F., Boccadoro, M., Palumbo, A., Petrucci, M. T., Cottone, F., Cannella, L., ... Cavo, M. (2018). A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: The CLARITY study protocol. *Health and Quality of Life Outcomes*, 16(1). <https://doi.org/10.1186/s12955-018-0953-4>
- Cerrato, C., Di Raimondo, F., De Paoli, L., Spada, S., Patriarca, F., Crippa, C., ... Gay, F. (2018). Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. *Journal of Cancer Research and Clinical Oncology*, 144(7), 1357–1366. <https://doi.org/10.1007/s00432-018-2641-5>
- Larocca, A., D'Agostino, M., & Boccadoro, M. (2018). Gentle yet effective combination therapy with novel agents in elderly multiple myeloma patients. *British Journal of Haematology*, 182(2), 165–167. <https://doi.org/10.1111/bjh.15260>
- Ludwig, H., Delforge, M., Facon, T., Einsele, H., Gay, F., Moreau, P., ... Sonneveld, P. (2018). Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network. *Leukemia*, 32(7), 1542–1560. <https://doi.org/10.1038/s41375-018-0040-1>
- Mina, R., Petrucci, M. T., Corradini, P., Spada, S., Patriarca, F., Cerrato, C., ... Bringhen, S. (2018). Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. *Clinical Lymphoma, Myeloma and Leukemia*, 18(8), 533–540. <https://doi.org/10.1016/j.clml.2018.05.019>
- Caers, J., Garderet, L., Kortüm, K. M., O'dwyer, M. E., van de Donk, N. W. C. J., Binder, M., ... Engelhardt, M. (2018). European myeloma network recommendations on tools for the diagnosis and monitoring of multiple

- myeloma: What to use and when. *Haematologica*, 103(11), 1772–1784. <https://doi.org/10.3324/haematol.2018.189159>
- Bringhen, S., Milan, A., Ferri, C., Wäsch, R., Gay, F., Larocca, A., ... Engelhardt, M. (2018). Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). *Haematologica*, 103(9), 1422–1432. <https://doi.org/10.3324/haematol.2018.191288>
- Crisà, E., Cilloni, D., Elli, E. M., Martinelli, V., Palumbo, G. A., Pugliese, N., ... Ferrero, D. (2018). The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib. *British Journal of Haematology*, 182(5), 701–704. <https://doi.org/10.1111/bjh.15450>
- Bringhen, S., Offidani, M., Palmieri, S., Pisani, F., Rizzi, R., Spada, S., ... Larocca, A. (2018). Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis. *Critical Reviews in Oncology/Hematology*, 130, 27–35. <https://doi.org/10.1016/j.critrevonc.2018.07.003>
- Salvini, M., D'Agostino, M., Bonello, F., Boccadoro, M., & Bringhen, S. (2018). Determining treatment intensity in elderly patients with multiple myeloma. *Expert Review of Anticancer Therapy*, 18(9), 917–930. <https://doi.org/10.1080/14737140.2018.1496823>
- Gay, F., Jackson, G., Rosiñol, L., Holstein, S. A., Moreau, P., Spada, S., ... Attal, M. (2018). Maintenance Treatment and Survival in Patients with Myeloma: A Systematic Review and Network Meta-analysis. *JAMA Oncology*, 4(10), 1389–1397. <https://doi.org/10.1001/jamaoncol.2018.2961>
- Gavriatopoulou, M., Musto, P., Caers, J., Merlini, G., Kastiris, E., van de Donk, N., ... Terpos, E. (2018). European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. *Leukemia*, 32(9), 1883–1898. <https://doi.org/10.1038/s41375-018-0209-7>
- Mohty, M., Terpos, E., Mateos, M.-V., Cavo, M., Lejniece, S., Beksac, M., ... Ludwig, H. (2018). Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. *Clinical Lymphoma, Myeloma and Leukemia*, 18(10), e401–e419. <https://doi.org/10.1016/j.clml.2018.06.018>
- Oliva, S., Troia, R., D'Agostino, M., Boccadoro, M., & Gay, F. (2018). Promises and pitfalls in the use of PD-1/PD-L1 inhibitors in multiple myeloma. *Frontiers in Immunology*, 9(NOV). <https://doi.org/10.3389/fimmu.2018.02749>
- Bonello, F., D'Agostino, M., Moscvin, M., Cerrato, C., Boccadoro, M., & Gay, F. (2018). CD38 as an immunotherapeutic target in multiple myeloma. *Expert Opinion on Biological Therapy*, 18(12), 1209–1221. <https://doi.org/10.1080/14712598.2018.1544240>
- Ghione, P., Cavallo, F., Visco, C., Chen, Z., Castellino, A., Tisi, M. C., ... Martin, P. (2018). A retrospective study of R-DHAP/Ox for early progressing follicular lymphoma. *British Journal of Haematology*, 183(5), 828–831. <https://doi.org/10.1111/bjh.15057>
- D'Agostino, M., De Paoli, L., Conticello, C., Offidani, M., Ria, R., Petrucci, M. T., ... Gay, F. (2018). Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials. *Critical Reviews in Oncology/Hematology*, 132, 9–16. <https://doi.org/10.1016/j.critrevonc.2018.09.008>
- Griggio, V., Mandili, G., Vitale, C., Capello, M., Macor, P., Serra, S., ... Coscia, M. (2017). Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia. *Oncotarget*, 8(2), 3274–3288. <https://doi.org/10.18632/oncotarget.13712>
- Oliva, S., Gambella, M., Gilestro, M., Muccio, V. E., Gay, F., Drandi, D., ... Omedè, P. (2017). Minimal residual disease after transplantation or lenalidomidebased consolidation in myeloma patients: A prospective analysis. *Oncotarget*, 8(4), 5924–5935. <https://doi.org/10.18632/oncotarget.12641>
- Crisà, E., Cerrano, M., Beggiato, E., Benevolo, G., Lanzarone, G., Manzini, P. M., ... Ferrero, D. (2017). Can pegylated interferon improve the outcome of polycythemia vera patients? *Journal of Hematology and Oncology*, 10(1). <https://doi.org/10.1186/s13045-017-0395-1>
- Maffini, E., Festuccia, M., Brunello, L., Boccadoro, M., Giaccone, L., & Bruno, B. (2017). Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, 23(3), 388–397. <https://doi.org/10.1016/j.bbmt.2016.12.632>
- Gay, F., Genuardi, M., & Boccadoro, M. (2017). Autologous transplant for myeloma: When the old meets the new. *Oncotarget*, 8(53), 90618–90619. <https://doi.org/10.18632/oncotarget.21605>

- Offidani, M., Corvatta, L., Bringhen, S., Gentili, S., Troia, R., Maracci, L., ... Boccadoro, M. (2017). Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma. *European Journal of Haematology*, 98(3), 289–295. <https://doi.org/10.1111/ejh.12834>
- Esma, F., Salvini, M., Troia, R., Boccadoro, M., Larocca, A., & Pautasso, C. (2017). Melphalan hydrochloride for the treatment of multiple myeloma. *Expert Opinion on Pharmacotherapy*, 18(11), 1127–1136. <https://doi.org/10.1080/14656566.2017.1349102>
- Larocca, A., Mina, R., Gay, F., Bringhen, S., & Boccadoro, M. (2017). Emerging drugs and combinations to treat multiple myeloma. *Oncotarget*, 8(36), 60656–60672. <https://doi.org/10.18632/oncotarget.19269>
- Aapro, M., Bokemeyer, C., Ludwig, H., Gascón, P., Boccadoro, M., Denhaerynck, K., ... Abraham, I. (2017). Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study). *Journal of Geriatric Oncology*, 8(2), 86–95. <https://doi.org/10.1016/j.jgo.2016.09.006>
- Ferrero, D., Cerrano, M., Crisà, E., Aguzzi, C., Giai, V., & Boccadoro, M. (2017). How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience. *British Journal of Haematology*, 176(4), 669–671. <https://doi.org/10.1111/bjh.13983>
- Oliva, S., Gambella, M., Boccadoro, M., & Bringhen, S. (2017). Systemic virotherapy for multiple myeloma. *Expert Opinion on Biological Therapy*, 17(11), 1375–1387. <https://doi.org/10.1080/14712598.2017.1364359>
- Salvini, M., Bonello, F., Boccadoro, M., & Larocca, A. (2017). Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma. *Expert Review of Anticancer Therapy*, 17(1), 75–87. <https://doi.org/10.1080/14737140.2017.1266264>
- Bokemeyer, C., Gascón, P., Aapro, M., Ludwig, H., Boccadoro, M., Denhaerynck, K., ... MacDonald, K. (2017). Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study. *Supportive Care in Cancer*, 25(6), 1819–1828. <https://doi.org/10.1007/s00520-017-3572-4>
- Vitale, C., Griggio, V., Todaro, M., Salvetti, C., Boccadoro, M., & Coscia, M. (2017). Magic pills: new oral drugs to treat chronic lymphocytic leukemia. *Expert Opinion on Pharmacotherapy*, 18(4), 411–425. <https://doi.org/10.1080/14656566.2017.1293655>
- Giaccone, L., Festuccia, M., Zallio, F., Sorasio, R., Brunello, L., Maffini, E., ... Bruno, B. (2017). Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma. *Bone Marrow Transplantation*, 52(8), 1208–1211. <https://doi.org/10.1038/bmt.2017.99>
- Gay, F., Oliva, S., Petrucci, M. T., Montefusco, V., Conticello, C., Musto, P., ... Boccadoro, M. (2017). Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: A pooled analysis. *Leukemia*, 31(8), 1727–1734. <https://doi.org/10.1038/leu.2016.381>
- Genadieva Stavric, S., Bonello, F., Bringhen, S., Boccadoro, M., & Larocca, A. (2017). How is patient care for multiple myeloma advancing? *Expert Review of Hematology*, 10(6), 551–561. <https://doi.org/10.1080/17474086.2017.1326814>
- Beccuti, M., Genuardi, E., Romano, G., Monitillo, L., Barbero, D., Boccadoro, M., ... Cordero, F. (2017). HashClone: A new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data. *BMC Bioinformatics*, 18(1). <https://doi.org/10.1186/s12859-017-1923-2>
- Gay, F., D'Agostino, M., Giaccone, L., Genuardi, M., Festuccia, M., Boccadoro, M., & Bruno, B. (2017). Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors. *Clinical Lymphoma, Myeloma and Leukemia*, 17(8), 471–478. <https://doi.org/10.1016/j.clml.2017.06.014>
- Zaccaria, G. M., Rosati, S., Castagneri, C., Ferrero, S., Ladetto, M., Boccadoro, M., & Balestra, G. (2017). Data quality improvement of a multicenter clinical trial dataset. In *Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society, EMBS* (pp. 1190–1193). <https://doi.org/10.1109/EMBC.2017.8037043>
- Boccadoro, M. (2017). Updated analysis of CALGB (Alliance) 100104. *The Lancet Haematology*, 4(9), e404–e405. [https://doi.org/10.1016/S2352-3026\(17\)30148-5](https://doi.org/10.1016/S2352-3026(17)30148-5)
- D'Agostino, M., Boccadoro, M., & Smith, E. L. (2017). Novel Immunotherapies for Multiple Myeloma. *Current Hematologic Malignancy Reports*, 12(4), 344–357. <https://doi.org/10.1007/s11899-017-0397-7>
- Grammatico, S., Bringhen, S., Vozella, F., Siniscalchi, A., Boccadoro, M., & Petrucci, M. T. (2017). Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter,

open-label Phase 1/2 study. *Leukemia and Lymphoma*, 58(11), 2738–2740. <https://doi.org/10.1080/10428194.2017.1307360>

Gascón, P., Aapro, M., Ludwig, H., Bokemeyer, C., Boccadoro, M., Turner, M., ... Abraham, I. (2016). Erratum to: Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study) (Support Care Cancer, (2016), 10.1007/s00520-015-2861-z). *Supportive Care in Cancer*, 24(2), 927. <https://doi.org/10.1007/s00520-015-2991-3>

Cerrano, M., Crisà, E., Gai, V., Boccadoro, M., & Ferrero, D. (2016). Anemia in the elderly: Not always what it seems. *Mediterranean Journal of Hematology and Infectious Diseases*, 8(1). <https://doi.org/10.4084/MJHID.2016.017>

Magarotto, V., Bringhen, S., Offidani, M., Benevolo, G., Patriarca, F., Mina, R., ... Palumbo, A. (2016). Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. *Blood*, 127(9), 1102–1108. <https://doi.org/10.1182/blood-2015-08-662627>

Muccio, V. E., Saraci, E., Gilestro, M., Gattei, V., Zucchetto, A., Astolfi, M., ... Omedè, P. (2016). Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents. *Cytometry Part B - Clinical Cytometry*, 90(1), 81–90. <https://doi.org/10.1002/cyto.b.21279>

Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., ... Avet-Loiseau, H. (2016). International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. *The Lancet Oncology*, 17(8), e328–e346. [https://doi.org/10.1016/S1470-2045\(16\)30206-6](https://doi.org/10.1016/S1470-2045(16)30206-6)

Gascón, P., Aapro, M., Ludwig, H., Bokemeyer, C., Boccadoro, M., Turner, M., ... Abraham, I. (2016). Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study). *Supportive Care in Cancer*, 24(2), 911–925. <https://doi.org/10.1007/s00520-015-2861-z>

Giaccone, L., Audisio, E., Bruno, B., Maffini, E., D'Ardia, S., Caracciolo, D., ... Marmont, F. (2016). Role of Chemotherapy and Allografting in the Treatment of Acute Lymphoblastic Leukemia. *Clinical Lymphoma, Myeloma and Leukemia*, 16(2), 96–103. <https://doi.org/10.1016/j.clml.2015.11.002>

Larocca, A., Bringhen, S., Petrucci, M. T., Oliva, S., Falcone, A. P., Caravita, T., ... Palumbo, A. (2016). A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma. *Leukemia*, 30(6), 1320–1326. <https://doi.org/10.1038/leu.2016.36>

Aapro, M., Ludwig, H., Bokemeyer, C., Gascón, P., Boccadoro, M., Denhaerynck, K., ... Abraham, I. (2016). Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study). *Annals of Oncology*, 27(11), 2039–2045. <https://doi.org/10.1093/annonc/mdw309>

Ladetto, M., Ferrero, S., Drandi, D., Festuccia, M., Patriarca, F., Mordini, N., ... Bruno, B. (2016). Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. *Leukemia*, 30(5), 1211–1214. <https://doi.org/10.1038/leu.2015.269>

Cerrano, M., Crisà, E., Gottardi, E., Aguzzi, C., Boccadoro, M., & Ferrero, D. (2016). Long-term therapy-free remission in a patient with platelet-derived growth factor receptor beta-rearranged myeloproliferative neoplasm. *American Journal of Hematology*, 91(9), E353. <https://doi.org/10.1002/ajh.24422>

Maffini, E., Giaccone, L., Festuccia, M., Brunello, L., Buondonno, I., Ferrero, D., ... Bruno, B. (2016). Ruxolitinib in steroid refractory graft-vs.-host disease: A case report. *Journal of Hematology and Oncology*, 9(1). <https://doi.org/10.1186/s13045-016-0298-6>

Bruno, B., Auner, H. W., Gahrton, G., Garderet, L., Festuccia, M., Ladetto, M., ... Kröger, N. (2016). Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting). *Leukemia and Lymphoma*, 57(6), 1256–1268. <https://doi.org/10.3109/10428194.2015.1131278>

Castagnetti, F., Gugliotta, G., Baccarani, M., Breccia, M., Specchia, G., Levato, L., ... D'Emilio, A. (2015). Differences among young adults, adults and elderly chronic myeloid leukemia patients. *Annals of Oncology*, 26(1), 185–192. <https://doi.org/10.1093/annonc/mdu490>

Gay, F., Oliva, S., Petrucci, M. T., Conticello, C., Catalano, L., Corradini, P., ... Palumbo, A. (2015). Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: A randomised, multicentre, phase 3 trial. *The Lancet Oncology*, 16(16), 1617–1629. [https://doi.org/10.1016/S1470-2045\(15\)00389-7](https://doi.org/10.1016/S1470-2045(15)00389-7)

- Ferrero, S., Ladetto, M., Drandi, D., Cavallo, F., Genuardi, E., Urbano, M., ... Palumbo, A. (2015). Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival. *Leukemia*, 29(3), 689–695. <https://doi.org/10.1038/leu.2014.219>
- Brioli, A., Perrone, G., Patriarca, F., Pezzi, A., Nobile, F., Ballerini, F., ... Cavo, M. (2015). Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation. *Bone Marrow Transplantation*, 50(5), 673–678. <https://doi.org/10.1038/bmt.2014.322>
- Festuccia, M., Martino, M., Ferrando, F., Messina, G., Moscato, T., Fedele, R., ... Bruno, B. (2015). Allogeneic stem cell transplantation in multiple myeloma: Immunotherapy and new drugs. *Expert Opinion on Biological Therapy*, 15(6), 857–872. <https://doi.org/10.1517/14712598.2015.1036735>
- Drandi, D., Kubiczkova-Besse, L., Ferrero, S., Dani, N., Passera, R., Mantoan, B., ... Ladetto, M. (2015). Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR. *Journal of Molecular Diagnostics*, 17(6), 652–660. <https://doi.org/10.1016/j.jmoldx.2015.05.007>
- Castella, B., Foglietta, M., Sciancalepore, P., Rigoni, M., Coscia, M., Griggio, V., ... Massaia, M. (2015). Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma. *OncImmunology*, 4(11). <https://doi.org/10.1080/2162402X.2015.1047580>
- Musto, P., Simeon, V., Grossi, A., Gay, F., Bringhen, S., Larocca, A., ... Boccadoro, M. (2015). Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: Results from a Gruppo Ital. *Stem Cell Research and Therapy*, 6(1). <https://doi.org/10.1186/s13287-015-0033-1>
- Palumbo, A., Gay, F., Cavallo, F., Raimondo, F. D., Larocca, A., Hardan, I., ... Boccadoro, M. (2015). Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma. *Journal of Clinical Oncology*, 33(30), 3459–3466. <https://doi.org/10.1200/JCO.2014.60.2466>
- Giaccone, L., Brunello, L., Festuccia, M., Gilestro, M., Maffini, E., Ferrando, F., ... Bruno, B. (2015). Clinical impact of immunophenotypic remission after allogeneic hematopoietic cell transplantation in multiple myeloma. *Bone Marrow Transplantation*, 50(4), 511–516. <https://doi.org/10.1038/bmt.2014.319>
- Rigoni, M., Riganti, C., Vitale, C., Griggio, V., Campia, I., Robino, M., ... Coscia, M. (2015). Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells. *Oncotarget*, 6(30), 29833–29846. <https://doi.org/10.18632/oncotarget.4006>
- Morabito, F., Bringhen, S., Larocca, A., Wijermans, P., Victoria Mateos, M., Gimsing, P., ... Offidani, M. (2014). Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. *American Journal of Hematology*, 89(4), 355–362. <https://doi.org/10.1002/ajh.23641>
- Ludwig, H., Sonneveld, P., Davies, F., Bladé, J., Boccadoro, M., Cavo, M., ... Palumbo, A. (2014). European perspective on multiple myeloma treatment strategies in 2014. *Oncologist*, 19(8), 829–844. <https://doi.org/10.1634/theoncologist.2014-0042>
- Ladetto, M., Brüggemann, M., Monitillo, L., Ferrero, S., Pepin, F., Drandi, D., ... Pott, C. (2014). Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. *Leukemia*, 28(6), 1299–1307. <https://doi.org/10.1038/leu.2013.375>
- Musto, P., Simeon, V., Martorelli, M. C., Petrucci, M. T., Cascavilla, N., Di Raimondo, F., ... Palumbo, A. (2014). Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. *Leukemia*, 28(1), 222–225. <https://doi.org/10.1038/leu.2013.241>
- Caltagirone, S., Ruggeri, M., Aschero, S., Gilestro, M., Oddolo, D., Gay, F., ... Omedè, P. (2014). Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies. *Haematologica*, 99(10), 1611–1617. <https://doi.org/10.3324/haematol.2014.103853>
- Palumbo, A., Bringhen, S., Larocca, A., Rossi, D., Di Raimondo, F., Magarotto, V., ... Cavo, M. (2014). Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: Updated follow-up and improved survival. *Journal of Clinical Oncology*, 32(7), 634–640. <https://doi.org/10.1200/JCO.2013.52.0023>
- Muccio, V. E., Saraci, E., Gilestro, M., Oddolo, D., Caltagirone, S. A., Boccadoro, M., & Omedé, P. (2014). Appropriateness of PNH clones search in peripheral blood | Appropriately della ricerca di cloni EPN nel

sangue periferico. *Rivista Italiana Della Medicina Di Laboratorio*, 10(2), 115–121. <https://doi.org/10.1007/s13631-014-0054-2>

Palumbo, A., Bringhen, S., Kumar, S. K., Lupparelli, G., Usmani, S., Waage, A., ... McCarthy, P. L. (2014). Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: A meta-analysis of individual patient data. *The Lancet Oncology*, 15(3), 333–342. [https://doi.org/10.1016/S1470-2045\(13\)70609-0](https://doi.org/10.1016/S1470-2045(13)70609-0)

Ferrero, D., Crisà, E., Marmont, F., Audisio, E., Frairia, C., Gai, V., ... Boccadoro, M. (2014). Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents. *Annals of Hematology*, 93(8), 1391–1400. <https://doi.org/10.1007/s00277-014-2047-7>

Gambella, M., Rocci, A., Passera, R., Gay, F., Omedè, P., Crippa, C., ... Palumbo, A. (2014). High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib. *Haematologica*, 99(2). <https://doi.org/10.3324/haematol.2013.090142>

Rocci, A., Hofmeister, C. C., Geyer, S., Stiff, A., Gambella, M., Cascione, L., ... Pichiorri, F. (2014). Circulating miRNA markers show promise as new prognosticators for multiple myeloma. *Leukemia*, 28(9), 1922–1926. <https://doi.org/10.1038/leu.2014.155>

Rocci, A., Gambella, M., Aschero, S., Baldi, I., Trusolino, L., Cavallo, F., ... Palumbo, A. (2014). MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients. *British Journal of Haematology*, 164(6), 841–850. <https://doi.org/10.1111/bjh.12719>

Bringhen, S., Petrucci, M. T., Larocca, A., Conticello, C., Rossi, D., Magarotto, V., ... Palumbo, A. (2014). Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: A multicenter, phase 2 study. *Blood*, 124(1), 63–69. <https://doi.org/10.1182/blood-2014-03-563759>

Festuccia, M., Giaccone, L., Gay, F., Brunello, L., Maffini, E., Ferrando, F., ... Bruno, B. (2014). Trichoderma species fungemia after high-dose chemotherapy and autologous stem cell transplantation: A case report. *Transplant Infectious Disease*, 16(4), 653–657. <https://doi.org/10.1111/tid.12245>

Mateos, M.-V., Bringhen, S., Richardson, P. G., Lahuerta, J. J., Larocca, A., Oriol, A., ... Palumbo, A. (2014). Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. *Haematologica*, 99(6), 1114–1122. <https://doi.org/10.3324/haematol.2013.099341>

Engelhardt, M., Terpos, E., Kleber, M., Gay, F., Wäsch, R., Morgan, G., ... Palumbo, A. (2014). European myeloma network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. *Haematologica*, 99(2), 232–242. <https://doi.org/10.3324/haematol.2013.099358>

Foglietta, M., Castella, B., Mariani, S., Coscia, M., Godio, L., Ferracini, R., ... Massaia, M. (2014). The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespective of the disease status. *Haematologica*, 99(10), 1605–1610. <https://doi.org/10.3324/haematol.2014.105866>

Gay, F., Magarotto, V., Crippa, C., Pescosta, N., Guglielmelli, T., Cavallo, F., ... Palumbo, A. (2014). Gay F, Magarotto V, Crippa C, et al. Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: Updated results. (Blood (2013) 122, 8 (1376-1383)). *Blood*, 123(24), 3843. <https://doi.org/10.1182/blood-2014-04-572073>

Palumbo, A., Cavallo, F., Gay, F., Di Raimondo, F., Yehuda, D. B., Petrucci, M. T., ... Cavo, M. (2014). Autologous transplantation and maintenance therapy in multiple myeloma. *New England Journal of Medicine*, 371(10), 895–905. <https://doi.org/10.1056/NEJMoa1402888>

Petrucci, M. T., Levi, A., Bringhen, S., Scotti, S., Gentilini, F., Russo, S., ... Palumbo, A. (2013). Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: A multicenter, open label phase 1/2 study. *Cancer*, 119(5), 971–977. <https://doi.org/10.1002/cncr.27820>

Falco, P., Cavallo, F., Larocca, A., Rossi, D., Guglielmelli, T., Rocci, A., ... Palumbo, A. (2013). Lenalidomide-prednisone induction followed by lenalidomide-melphalan- prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. *Leukemia*, 27(3), 695–701. <https://doi.org/10.1038/leu.2012.271>

Palumbo, A., Waage, A., Hulin, C., Beksac, M., Zweegman, S., Gay, F., ... Sonneveld, P. (2013). Safety of thalidomide in newly diagnosed elderly myeloma patients: A meta-analysis of data from individual patients in six randomized trials. *Haematologica*, 98(1), 87–94. <https://doi.org/10.3324/haematol.2012.067058>

- Mosca, L., Musto, P., Todoerti, K., Barbieri, M., Agnelli, L., Fabris, S., ... Neri, A. (2013). Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. *American Journal of Hematology*, 88(1), 16–23. <https://doi.org/10.1002/ajh.23339>
- Alessandrino, E. P., Porta, M. G. D., Malcovati, L., Jackson, C. H., Pascutto, C., Bacigalupo, A., ... Raimondi, R. (2013). Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. *American Journal of Hematology*, 88(7), 581–588. <https://doi.org/10.1002/ajh.23458>
- Lobetti Bodoni, C., Mantoan, B., Monitillo, L., Genuardi, E., Drandi, D., Barbero, D., ... Ladetto, M. (2013). Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma. *Therapeutic Advances in Hematology*, 4(3), 189–198. <https://doi.org/10.1177/2040620713480522>
- Passera, R., Pollichieni, S., Brunello, L., Patriarca, F., Bonifazi, F., Montefusco, V., ... Bruno, B. (2013). Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: Study from the Italian bone marrow donor registry. *Biology of Blood and Marrow Transplantation*, 19(6), 940–948. <https://doi.org/10.1016/j.bbmt.2013.03.012>
- Todoerti, K., Agnelli, L., Fabris, S., Lionetti, M., Tuana, G., Mosca, L., ... Musto, P. (2013). Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome. *Clinical Cancer Research*, 19(12), 3247–3258. <https://doi.org/10.1158/1078-0432.CCR-12-3461>
- Astolfi, M., Omedè, P., Redoglia, V., Oddolo, D., Ferrero, M. P., Ciaiolo, C., ... Boccadoro, M. (2013). Simultaneous evaluation of serum Hevylite and Freelite assays for relapse prediction in multiple myeloma | Analisi combinata dei saggi Hevylite e Freelite nella valutazione precoce della recidiva di mieloma multiplo. *Biochimica Clinica*, 37(5), 383–388.
- Cerrano, M., Crisà, E., Pregno, P., Aguzzi, C., Riccomagno, P., Boccadoro, M., & Ferrero, D. (2013). Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: A retrospective study on 91 unselected patients. *American Journal of Hematology*, 88(10), 838–842. <https://doi.org/10.1002/ajh.23501>
- Bringhen, S., Mateos, M. V., Zweegman, S., Larocca, A., Falcone, A. P., Oriol, A., ... Palumbo, A. (2013). Age and organ damage correlate with poor survival in myeloma patients: Meta-analysis of 1435 individual patient data from 4 randomized trials. *Haematologica*, 98(6), 980–987. <https://doi.org/10.3324/haematol.2012.075051>
- Quaglino, P., Nardò, T., Fierro, M. T., Massaia, M., Orsucci, L., Fava, P., ... Bernengo, M. G. (2013). Clinicopathologic spectrum of cutaneous diseases in patients with hematologic malignancies with or without allogeneic bone marrow transplantation: An observational cohort study in 101 patients. *Giornale Italiano Di Dermatologia e Venereologia*, 148(5), 453–463.
- Gay, F., Magarotto, V., Crippa, C., Pescosta, N., Guglielmelli, T., Cavallo, F., ... Palumbo, A. (2013). Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: Updated results. *Blood*, 122(8), 1376–1383. <https://doi.org/10.1182/blood-2013-02-483073>
- Larocca, A., Montefusco, V., Bringhen, S., Rossi, D., Crippa, C., Mina, R., ... Palumbo, A. (2013). Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: A multicenter phase 1/2 open-label study. *Blood*, 122(16), 2799–2806. <https://doi.org/10.1182/blood-2013-03-488676>
- Lionetti, M., Musto, P., Martino, M. T. D., Fabris, S., Agnelli, L., Todoerti, K., ... Neri, A. (2013). Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. *Clinical Cancer Research*, 19(12), 3130–3142. <https://doi.org/10.1158/1078-0432.CCR-12-2043>
- Larocca, A., Child, J. A., Cook, G., Jackson, G. H., Russell, N., Szubert, A., ... Morgan, G. J. (2013). The impact of response on bone-directed therapy in patients with multiple myeloma. *Blood*, 122(17), 2974–2977. <https://doi.org/10.1182/blood-2013-04-498139>
- Petrucci, M. T., Calabrese, E., Levi, A., Federico, V., Ceccolini, M., Rizzi, R., ... Foa, R. (2013). Cost of illness in patients with multiple myeloma in Italy: The CoMiM study. *Tumori*, 99(4). <https://doi.org/10.1700/1361.15125>
- Ferrero, S., Monitillo, L., Mantoan, B., Barbero, D., Genuardi, E., Barbiero, S., ... Ladetto, M. (2013). Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma. *Annals of Hematology*, 92(11), 1503–1511. <https://doi.org/10.1007/s00277-013-1797-y>
- Barosi, G., Merlini, G., Billio, A., Boccadoro, M., Corradini, P., Marchetti, M., ... Tura, S. (2012). SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. *Annals of Hematology*, 91(6), 875–888. <https://doi.org/10.1007/s00277-012-1445-y>

- Ferrero, S., Capello, D., Svaldi, M., Boi, M., Gatti, D., Drandi, D., ... Ladetto, M. (2012). Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. *Haematologica*, 97(6), 849–853. <https://doi.org/10.3324/haematol.2011.052852>
- Ludwig, H., Avet-Loiseau, H., Bladé, J., Boccadoro, M., Cavenagh, J., Cavo, M., ... Palumbo, A. (2012). European perspective on multiple myeloma treatment strategies: Update following recent congresses. *Oncologist*, 17(5), 592–606. <https://doi.org/10.1634/theoncologist.2011-0391>
- Palumbo, A., Bladé, J., Boccadoro, M., Palladino, C., Davies, F., Dimopoulos, M., ... San Miguel, J. (2012). How to manage neutropenia in multiple myeloma. *Clinical Lymphoma, Myeloma and Leukemia*, 12(1), 5–11. <https://doi.org/10.1016/j.clml.2011.11.001>
- Larocca, A., Cavallo, F., Mina, R., Boccadoro, M., & Palumbo, A. (2012). Current treatment strategies with lenalidomide in multiple myeloma and future perspectives. *Future Oncology*, 8(10), 1223–1238. <https://doi.org/10.2217/fon.12.124>
- Messina, G., Giaccone, L., Festuccia, M., Irrera, G., Scortechini, I., Sorasio, R., ... Bruno, B. (2012). Multicenter Experience Using Total Lymphoid Irradiation and Antithymocyte Globulin as Conditioning for Allografting in Hematological Malignancies. *Biology of Blood and Marrow Transplantation*, 18(10), 1600–1607. <https://doi.org/10.1016/j.bbmt.2012.03.012>
- Musto, P., Pagano, L., Petrucci, M. T., Morabito, F., Caravita, T., Di Raimondo, F., ... Palumbo, A. (2012). Primary plasma cell leukemia in the era of new drugs: Has something changed? *Critical Reviews in Oncology/Hematology*, 82(2), 141–149. <https://doi.org/10.1016/j.critrevonc.2011.04.005>
- Larocca, A., Cavallo, F., Bringhen, S., Di Raimondo, F., Falanga, A., Evangelista, A., ... Palumbo, A. (2012). Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. *Blood*, 119(4), 933–939. <https://doi.org/10.1182/blood-2011-03-344333>
- Coscia, M., Vitale, C., Peola, S., Foglietta, M., Rigoni, M., Griggio, V., ... Massaia, M. (2012). Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. *Blood*, 120(16), 3271–3279. <https://doi.org/10.1182/blood-2012-03-417519>
- Cavo, M., Pantani, L., Petrucci, M. T., Patriarca, F., Zamagni, E., Donnarumma, D., ... Palumbo, A. (2012). Bortezomib-thalidomide-dexamethasone is superior to thalidomide- dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. *Blood*, 120(1), 9–19. <https://doi.org/10.1182/blood-2012-02-408898>
- Crisà, E., Foli, C., Passera, R., Darbesio, A., Garvey, K. B., Boccadoro, M., & Ferrero, D. (2012). Long-term follow-up of myelodysplastic syndrome patients with moderate/severe anaemia receiving human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3: Independent positive impact of erythroid response on survival. *British Journal of Haematology*, 158(1), 99–107. <https://doi.org/10.1111/j.1365-2141.2012.09125.x>
- Bringhen, S., Gay, F., Pautasso, C., Cerrato, C., Boccadoro, M., & Palumbo, A. (2012). Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma. *Expert Opinion on Drug Metabolism and Toxicology*, 8(9), 1209–1222. <https://doi.org/10.1517/17425255.2012.712685>
- Magarotto, V., Boccadoro, M., & Palumbo, A. (2012). *Role of immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma in elderly patients. Immunomodulating Drugs for the Treatment of Cancer.*
- Lobetti-Bodoni, C., Ferrero, D., Genuardi, E., Passera, R., Bernocco, E., Sia, D., ... Ladetto, M. (2012). Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: Evidence for premature aging of the myeloid compartment. *Mechanisms of Ageing and Development*, 133(7), 479–488. <https://doi.org/10.1016/j.mad.2012.05.007>
- Offidani, M., Polloni, C., Cavallo, F., Marina Liberati, A., Ballanti, S., Pulini, S., ... Palumbo, A. (2012). Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. *Leukemia and Lymphoma*, 53(9), 1722–1727. <https://doi.org/10.3109/10428194.2012.664844>
- Guglielmelli, T., Bringhen, S., Rrodhe, S., Gay, F., Cavallo, F., Berruti, A., ... Palumbo, A. (2011). Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients. *European Journal of Cancer*, 47(6), 814–818. <https://doi.org/10.1016/j.ejca.2010.12.026>
- Gay, F., Larocca, A., Wijermans, P., Cavallo, F., Rossi, D., Schaafsma, R., ... Palumbo, A. (2011). Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with

novel agents: Analysis of 1175 patients. *Blood*, 117(11), 3025–3031. <https://doi.org/10.1182/blood-2010-09-307645>

Coscia, M., Pantaleoni, F., Riganti, C., Vitale, C., Rigoni, M., Peola, S., ... Massaia, M. (2011). IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. *Leukemia*, 25(5), 828–837. <https://doi.org/10.1038/leu.2011.12>

Bruno, B., Gay, F., Boccadoro, M., & Palumbo, A. (2011). Management of myeloma: An italian perspective. *Clinical Lymphoma, Myeloma and Leukemia*, 11(SUPPL.1). <https://doi.org/10.1016/j.clml.2011.03.026>

Palumbo, A., Cavo, M., Bringhen, S., Zamagni, E., Romano, A., Patriarca, F., ... Boccadoro, M. (2011). Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: A phase III, open-label, randomized trial. *Journal of Clinical Oncology*, 29(8), 986–993. <https://doi.org/10.1200/JCO.2010.31.6844>

Cavallo, F., Bringhen, S., Milone, G., Ben-Yehuda, D., Nagler, A., Calabrese, E., ... Palumbo, A. (2011). Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. *Leukemia*, 25(10), 1627–1631. <https://doi.org/10.1038/leu.2011.131>

Castella, B., Riganti, C., Fiore, F., Pantaleoni, F., Caneparì, M. E., Peola, S., ... Massaia, M. (2011). Immune modulation by zoledronic acid in human myeloma: An advantageous cross-talk between V γ 9V δ 2 T cells, $\alpha\beta$ CD8⁺ T cells, regulatory T cells, and dendritic cells. *Journal of Immunology*, 187(4), 1578–1590. <https://doi.org/10.4049/jimmunol.1002514>

Palumbo, A., Bringhen, S., Ludwig, H., Dimopoulos, M. A., Bladé, J., Mateos, M. V., ... Sonneveld, P. (2011). Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN). *Blood*, 118(17), 4519–4529. <https://doi.org/10.1182/blood-2011-06-358812>

Dimopoulos, M., Kyle, R., Feraud, J.-P., Rajkumar, S. V., San Miguel, J., Chanan-Khan, A., ... Jagannath, S. (2011). Consensus recommendations for standard investigative workup: Report of the International Myeloma Workshop Consensus Panel 3. *Blood*, 117(18), 4701–4705. <https://doi.org/10.1182/blood-2010-10-299529>

Giaccone, L., Storer, B., Patriarca, F., Rotta, M., Sorasio, R., Allione, B., ... Bruno, B. (2011). Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. *Blood*, 117(24), 6721–6727. <https://doi.org/10.1182/blood-2011-03-339945>

Moreau, P., Cavallo, F., Leleu, X., Hulin, C., Amiot, M., Descamps, G., ... Harousseau, J. L. (2011). Phase i study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma. *Leukemia*, 25(5), 872–874. <https://doi.org/10.1038/leu.2011.4>

Benevolo, G., Larocca, A., Gentile, M., Pugno, P., Gay, F., Botto, B., ... Palumbo, A. (2011). The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens. *Cancer*, 117(9), 1884–1890. <https://doi.org/10.1002/cncr.25743>

Gascón, P., Aapro, M., Ludwig, H., Rosencher, N., Boccadoro, M., Turner, M., ... Abraham, I. (2011). Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments. *Critical Reviews in Oncology/Hematology*, 77(3), 198–200. <https://doi.org/10.1016/j.critrevonc.2011.01.006>

Morabito, F., Gentile, M., Mazzone, C., Rossi, D., Di Raimondo, F., Bringhen, S., ... Palumbo, A. (2011). Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. *Blood*, 118(22), 5759–5766. <https://doi.org/10.1182/blood-2011-05-353995>

Cavo, M., Rajkumar, S. V., Palumbo, A., Moreau, P., Orłowski, R., Bladé, J., ... Lonial, S. (2011). International myeloma working group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. *Blood*, 117(23), 6063–6073. <https://doi.org/10.1182/blood-2011-02-297325>

Ruella, M., Rocci, A., Ricca, I., Carniti, C., Bodoni, C. L., Ladetto, M., ... Tarella, C. (2010). Comparative assessment of telomere length before and after hematopoietic SCT: Role of grafted cells in determining post-transplant telomere status. *Bone Marrow Transplantation*, 45(3), 505–512. <https://doi.org/10.1038/bmt.2009.297>

- Palumbo, A., Larocca, A., Falco, P., Sanpaolo, G., Falcone, A. P., Federico, V., ... Boccadoro, M. (2010). Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. *Leukemia*, 24(5), 1037–1042. <https://doi.org/10.1038/leu.2010.58>
- Ludwig, H., Beksac, M., Bladé, J., Boccadoro, M., Cavenagh, J., Cavo, M., ... Zweegman, S. (2010). Current multiple myeloma treatment strategies with novel agents: A European perspective. *Oncologist*, 15(1), 6–25. <https://doi.org/10.1634/theoncologist.2009-0203>
- Palumbo, A., Larocca, A., Genuardi, M., Kotwica, K., Gay, F., Rossi, D., ... Richardson, P. (2010). Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: Results of a multicenter phase I/II trial. *Haematologica*, 95(7), 1144–1149. <https://doi.org/10.3324/haematol.2009.017913>
- Giaccone, L., Festuccia, M., Marengo, A., Resta, I., Sorasio, R., Pittaluga, F., ... Marzano, A. (2010). Hepatitis B Virus Reactivation and Efficacy of Prophylaxis with Lamivudine in Patients Undergoing Allogeneic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, 16(6), 809–817. <https://doi.org/10.1016/j.bbmt.2009.12.533>
- Ladetto, M., Pagliano, G., Ferrero, S., Cavallo, F., Drandi, D., Santo, L., ... Palumbo, A. (2010). Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. *Journal of Clinical Oncology*, 28(12), 2077–2084. <https://doi.org/10.1200/JCO.2009.23.7172>
- Crisà, E., Venturino, E., Passera, R., Prina, M., Schinco, P., Borchellini, A., ... Ferrero, D. (2010). A retrospective study on 226 polycythemia vera patients: Impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs. *Annals of Hematology*, 89(7), 691–699. <https://doi.org/10.1007/s00277-009-0899-z>
- Palumbo, A., Bringhen, S., Bruno, B., Falcone, A. P., Liberati, A. M., Grasso, M., ... Boccadoro, M. (2010). Melphalan 200 mg/m² versus melphalan 100 mg/m² in newly diagnosed myeloma patients: A prospective, multicenter phase 3 study. *Blood*, 115(10), 1873–1879. <https://doi.org/10.1182/blood-2009-09-241737>
- Santo, L., Vallet, S., Hideshima, T., Cirstea, D., Ikeda, H., Pozzi, S., ... Raje, N. (2010). AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3B activation and RNA polymerase II inhibition. *Oncogene*, 29(16), 2325–2336. <https://doi.org/10.1038/onc.2009.510>
- Coscia, M., Quaglino, E., Iezzi, M., Curcio, C., Pantaleoni, F., Riganti, C., ... Massaia, M. (2010). Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. *Journal of Cellular and Molecular Medicine*, 14(12), 2803–2815. <https://doi.org/10.1111/j.1582-4934.2009.00926.x>
- Gay, F., Vincent Rajkumar, S. S., Falco, P., Kumar, S., Dispenzieri, A., Petrucci, M. T., ... Palumbo, A. (2010). Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: A retrospective study in newly diagnosed elderly myeloma. *European Journal of Haematology*, 85(3), 200–208. <https://doi.org/10.1111/j.1600-0609.2010.01469.x>
- Lobetti-Bodoni, C., Bernocco, E., Genuardi, E., Boccadoro, M., & Ladetto, M. (2010). Telomeres and telomerase in normal and malignant B-cells. *Hematological Oncology*, 28(4), 157–167. <https://doi.org/10.1002/hon.937>
- Palumbo, A., Bringhen, S., Rossi, D., Cavalli, M., Larocca, A., Ria, R., ... Boccadoro, M. (2010). Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: A randomized controlled trial. *Journal of Clinical Oncology*, 28(34), 5101–5109. <https://doi.org/10.1200/JCO.2010.29.8216>
- Palumbo, A., Gay, F., Falco, P., Crippa, C., Montefusco, V., Patriarca, F., ... Boccadoro, M. (2010). Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. *Journal of Clinical Oncology*, 28(5), 800–807. <https://doi.org/10.1200/JCO.2009.22.7561>
- Morabito, F., Gentile, M., Ciolli, S., Petrucci, M. T., Galimberti, S., Mele, G., ... Cavo, M. (2010). Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: A retrospective study of Italian Myeloma Network GIMEMA. *European Journal of Haematology*, 84(3), 223–228. <https://doi.org/10.1111/j.1600-0609.2009.01385.x>
- Engelhardt, M., Udi, J., Kleber, M., Spencer, A., Rocci, A., Knop, S., ... Palumbo, A. (2010). European Myeloma Network: The 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. *Leukemia and Lymphoma*, 51(11), 2006–2011. <https://doi.org/10.3109/10428194.2010.516378>
- Kyle, R. A., Durie, B. G. M., Rajkumar, S. V., Landgren, O., Blade, J., Merlini, G., ... Boccadoro, M. (2010). Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple

myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. *Leukemia*, 24(6), 1121–1127. <https://doi.org/10.1038/leu.2010.60>

Engelhardt, M., Kleber, M., Udi, J., Wsch, R., Spencer, A., Patriarca, F., ... Palumbo, A. (2010). Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: From standard therapy to novel approaches. *Leukemia and Lymphoma*, 51(8), 1424–1443. <https://doi.org/10.3109/10428194.2010.487959>

Offidani, M., Leoni, P., Bringhen, S., Corvatta, L., Larocca, A., Gentili, S., ... Palumbo, A. (2010). Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: A case-match study. *Leukemia and Lymphoma*, 51(8), 1444–1449. <https://doi.org/10.3109/10428194.2010.486878>

Ludwig, H., Bolejack, V., Crowley, J., Bladé, J., San Miguel, J., Kyle, R. A., ... Durie, B. (2010). Survival and years of life lost in different age cohorts of patients with multiple myeloma. *Journal of Clinical Oncology*, 28(9), 1599–1605. <https://doi.org/10.1200/JCO.2009.25.2114>

Bringhen, S., Larocca, A., Rossi, D., Cavalli, M., Genuardi, M., Ria, R., ... Palumbo, A. (2010). Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. *Blood*, 116(23), 4745–4753. <https://doi.org/10.1182/blood-2010-07-294983>

Bruno, B., Giaccone, L., Festuccia, M., & Boccadoro, M. (2010). Role of allogeneic transplantation in multiple drugs in the era of new drugs. *Mediterranean Journal of Hematology and Infectious Diseases*, 2(2). <https://doi.org/10.4084/MJHID.2010.013>

Squadrone, V., Massaia, M., Bruno, B., Marmont, F., Falda, M., Bagna, C., ... Ranieri, V. M. (2010). Early CPAP prevents evolution of acute lung injury in patients with hematologic malignancy. *Intensive Care Medicine*, 36(10), 1666–1674. <https://doi.org/10.1007/s00134-010-1934-1>

Palumbo, A., Sezer, O., Kyle, R., Miguel, J. S., Orlowski, R. Z., Moreau, P., ... Lonial, S. (2009). International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. *Leukemia*, 23(10), 1716–1730. <https://doi.org/10.1038/leu.2009.122>

Dispenzieri, A., Kyle, R., Merlini, G., Miguel, J. S., Ludwig, H., Hajek, R., ... Durie, B. G. M. (2009). International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. *Leukemia*, 23(2), 215–224. <https://doi.org/10.1038/leu.2008.307>

Rossi, D., Bondoni, C. L., Genuardi, E., Monitillo, L., Drandi, D., Cerri, M., ... Ladetto, M. (2009). Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. *Leukemia*, 23(6), 1062–1072. <https://doi.org/10.1038/leu.2008.399>

Giralt, S., Stadtmauer, E. A., Harousseau, J. L., Palumbo, A., Bensinger, W., Comenzo, R. L., ... Durie, B. G. M. (2009). International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). *Leukemia*, 23(10), 1904–1912. <https://doi.org/10.1038/leu.2009.127>

Richardson, P. G., Sonneveld, P., Schuster, M. W., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., ... San Miguel, J. (2009). Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline. *British Journal of Haematology*, 144(6), 895–903. <https://doi.org/10.1111/j.1365-2141.2008.07573.x>

Bruno, B., Giaccone, L., Sorasio, R., & Boccadoro, M. (2009). Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma. *Seminars in Hematology*, 46(2), 158–165. <https://doi.org/10.1053/j.seminhematol.2009.02.001>

Patriarca, F., Petrucci, M. T., Bringhen, S., Baldini, L., Caravita, T., Corradini, P., ... Palumbo, A. (2009). Considerations in the treatment of multiple myeloma: A consensus statement from Italian experts. *European Journal of Haematology*, 82(2), 93–105. <https://doi.org/10.1111/j.1600-0609.2008.01179.x>

Bruno, B., Rotta, M., Patriarca, F., Mattei, D., Allione, B., Carnevale-Schianca, F., ... Boccadoro, M. (2009). Nonmyeloablative allografting for newly diagnosed multiple myeloma: The experience of the Gruppo Italiano Trapianti di Midollo. *Blood*, 113(14), 3375–3382. <https://doi.org/10.1182/blood-2008-07-167379>

Mitsiades, C. S., Rouleau, C., Echart, C., Menon, K., Teicher, B., Distaso, M., ... Richardson, P. G. (2009). Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias. *Clinical Cancer Research*, 15(4), 1210–1221. <https://doi.org/10.1158/1078-0432.CCR-08-1270>

Musto, P., D'Auria, F., Pietrantonio, G., Baldini, L., Bringhen, S., Caravita, T., ... Palumbo, A. (2009). First-line treatment of multiple myeloma in elderly patients: The GIMEMA (Gruppo Italiano Malattie EMatologiche

- dell'Adulto) multiple myeloma working party perspective. *Current Drug Targets*, 10(10), 906–922. <https://doi.org/10.2174/138945009789577936>
- Palumbo, A., Falco, P., Falcone, A., Benevolo, G., Canepa, L., Gay, F., ... Petrucci, M. T. (2009). Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: Kinetics of neutropenia and thrombocytopenia and time-to-event results. *Clinical Lymphoma and Myeloma*, 9(2), 145–150. <https://doi.org/10.3816/CLM.2009.n.035>
- Farina, L., Bruno, B., Patriarca, F., Spina, F., Sorasio, R., Morelli, M., ... Corradini, P. (2009). The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. *Leukemia*, 23(6), 1131–1138. <https://doi.org/10.1038/leu.2009.1>
- Giarin, M. M., Giaccone, L., Sorasio, R., Sfiligoi, C., Amoroso, B., Cavallo, F., ... Boccadoro, M. (2009). Serum free light chain ratio, total κ/λ ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. *Clinical Chemistry*, 55(8), 1510–1516. <https://doi.org/10.1373/clinchem.2009.124370>
- Terpos, E., Sezer, O., Croucher, P. I., García-Sanz, R., Boccadoro, M., San Miguel, J., ... Sonneveld, P. (2009). The use of bisphosphonates in multiple myeloma: Recommendations of an expert panel on behalf of the European Myeloma Network. *Annals of Oncology*, 20(8), 1303–1317. <https://doi.org/10.1093/annonc/mdn796>
- Ferrero, D., Darbesio, A., Gai, V., Genuardi, M., Dellacasa, C. M., Sorasio, R., ... Boccadoro, M. (2009). Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes. *British Journal of Haematology*, 144(3), 342–349. <https://doi.org/10.1111/j.1365-2141.2008.07465.x>
- Ludwig, H., Durie, B. G. M., Bolejack, V., Turesson, I., Kyle, R. A., Blade, J., ... Crowley, J. (2008). Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: An analysis of 10 549 patients from the International Myeloma Working Group. *Blood*, 111(8), 4039–4047. <https://doi.org/10.1182/blood-2007-03-081018>
- Palumbo, A., Facon, T., Sonneveld, P., Bladè, J., Offidani, M., Gay, F., ... Harousseau, J.-L. (2008). Thalidomide for treatment of multiple myeloma: 10 years later. *Blood*, 111(8), 3968–3977. <https://doi.org/10.1182/blood-2007-10-117457>
- Palumbo, A., Magarotto, V., Gay, F., Falco, P., Bringhen, S., & Boccadoro, M. (2008). *Update on recent developments for patients with newly diagnosed multiple myeloma*. *Annals of the New York Academy of Sciences* (Vol. 1138). <https://doi.org/10.1196/annals.1414.004>
- Palumbo, A., Gay, F., Bringhen, S., Falcone, A., Pescosta, N., Callea, V., ... Boccadoro, M. (2008). Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. *Annals of Oncology*, 19(6), 1160–1165. <https://doi.org/10.1093/annonc/mdn018>
- Ladetto, M., De Marco, F., Benedetti, F., Vitolo, U., Parti, C., Rambaldi, A., ... Tarella, C. (2008). Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: The superior disease control of R-HDS does not translate into an overall survival. *Blood*, 111(8), 4004–4013. <https://doi.org/10.1182/blood-2007-10-116749>
- Palumbo, A., Rajkumar, S. V., Dimopoulos, M. A., Richardson, P. G., San Miguel, J., Barlogie, B., ... Hussein, M. A. (2008). Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. *Leukemia*, 22(2), 414–423. <https://doi.org/10.1038/sj.leu.2405062>
- Musto, P., Petrucci, M. T., Bringhen, S., Guglielmelli, T., Caravita, T., Bongarzone, V., ... Palumbo, A. (2008). A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. *Cancer*, 113(7), 1588–1595. <https://doi.org/10.1002/cncr.23783>
- Palumbo, A., Bringhen, S., Liberati, A. M., Caravita, T., Falcone, A., Callea, V., ... Boccadoro, M. (2008). Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: Updated results of a randomized controlled trial. *Blood*, 112(8), 3107–3114. <https://doi.org/10.1182/blood-2008-04-149427>
- Pichiorri, F., Suh, S.-S., Ladetto, M., Kuehl, M., Palumbo, T., Drandi, D., ... Croce, C. M. (2008). MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. *Proceedings of the National Academy of Sciences of the United States of America*, 105(35), 12885–12890. <https://doi.org/10.1073/pnas.0806202105>

- Palumbo, A., Falco, P., Gay, F., Magarotto, V., Patriarca, F., Nozzoli, C., & Boccadoro, M. (2008). From cell biology to therapy: Lenalidomide in untreated multiple myeloma. *Haematologica Meeting Reports*, 2(5), 94–97.
- San-Miguel, J. F., Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., ... Anderson, K. C. (2008). Efficacy and safety of bortezomib in patients with renal impairment: Results from the APEX phase 3 study. *Leukemia*, 22(4), 842–849. <https://doi.org/10.1038/sj.leu.2405087>
- Tarella, C., Zanni, M., Magni, M., Benedetti, F., Patti, C., Barbui, T., ... Rambaldi, A. (2008). Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: A multicenter Gruppo Italiano Terapie Innovative nei Linfomi survey. *Journal of Clinical Oncology*, 26(19), 3166–3175. <https://doi.org/10.1200/JCO.2007.14.4204>
- Vallet, S., Palumbo, A., Raje, N., Boccadoro, M., & Anderson, K. C. (2008). Thalidomide and lenalidomide: Mechanism-based potential drug combinations. *Leukemia and Lymphoma*, 49(7), 1238–1245. <https://doi.org/10.1080/10428190802005191>
- Bruno, B., Giaccone, L., Sorasio, R., Ladetto, M., Novero, D., Omedè, P., & Boccadoro, M. (2008). Evidence of the graft-versus-tumor effect after reduced-intensity transplant | Evidenza dell'effetto trapianto versus tumore dopo trapianto ad intensità ridotta. *Haematologica Meeting Reports*, 2(6), 49–53.
- Larocca, A., Cavallo, F., Magarotto, V., Rossi, D., Patriarca, F., Boccadoro, M., & Palumbo, A. (2008). Defibrotide: A review on clinical use and future development. *Expert Opinion on Biological Therapy*, 8(8), 1201–1212. <https://doi.org/10.1517/14712598.8.8.1201>
- Palumbo, A., Magarotto, V., Larocca, A., Bringhen, S., Falco, P., Di Raimondo, F., ... Boccadoro, M. (2008). Treatment of newly diagnosed multiple myeloma. *Current Hematologic Malignancy Reports*, 3(2), 107–114. <https://doi.org/10.1007/s11899-008-0016-8>
- Musto, P., Petrucci, M. T., Bringhen, S., Guglielmelli, T., Caravita, T., Bongarzone, V., ... Palumbo, A. (2008). A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma (Cancer (2008) 113, (1588-1595)). *Cancer*, 113(10), 2835. <https://doi.org/10.1002/cncr.23966>
- Musto, P., D'Auria, F., Pietrantonio, G., Bringhen, S., Morabito, F., Di Raimondo, F., ... Palumbo, A. (2008). Role of thalidomide in previously untreated patients with multiple myeloma. *Expert Review of Anticancer Therapy*, 8(10), 1569–1580. <https://doi.org/10.1586/14737140.8.10.1569>
- Falco, P., Cavallo, F., Larocca, A., Liberati, A. M., Musto, P., Boccadoro, M., & Palumbo, A. (2008). Lenalidomide and its role in the management of multiple myeloma. *Expert Review of Anticancer Therapy*, 8(6), 865–874. <https://doi.org/10.1586/14737140.8.6.865>
- Montefusco, V., Gay, F., Spina, F., Miceli, R., Maniezzo, M., Teresa Ambrosini, M., ... Corradini, P. (2008). Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. *Leukemia and Lymphoma*, 49(11), 2156–2162. <https://doi.org/10.1080/10428190802483778>
- Dicato, M., Boccadoro, M., Cavenagh, J., Harousseau, J.-L., Ludwig, H., San Miguel, J., & Sonneveld, P. (2007). Management of multiple myeloma with bortezomib: Experts review the data and debate the issues. *Oncology*, 70(6), 474–482. <https://doi.org/10.1159/000099284>
- Cavallo, F., Ambrosini, M. T., Rus, C., Boccadoro, M., & Palumbo, A. (2007). The treatment of the elderly multiple myeloma patients. *Leukemia and Lymphoma*, 48(3), 469–480. <https://doi.org/10.1080/10428190601059852>
- Tarella, C., Zanni, M., Di Nicola, M., Patti, C., Calvi, R., Pescarollo, A., ... Gianni, A. M. (2007). Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: A multicenter study by GITIL (Gruppo Italiano. *Leukemia*, 21(8), 1802–1811. <https://doi.org/10.1038/sj.leu.2404781>
- Bruno, B., Ciccone, G., & Boccadoro, M. (2007). The authors reply [4]. *New England Journal of Medicine*, 356(25), 2647–2648.
- Conrotto, D., Carrozzo, M., Ubertalli, A. V., Gandolfo, S., Giaccone, L., Boccadoro, M., & Bruno, B. (2007). Erratum: Dramatic increase of tacrolimus plasma concentration during topical treatment for oral graft-versus-host disease (Transplantation (2006) 82, (1113)). *Transplantation*, 83(1), 76. <https://doi.org/10.1097/00007890-200701150-00015>

- Bruno, B., Rotta, M., Patriarca, F., Mordini, N., Allione, B., Carnevale-Schianca, F., ... Boccadoro, M. (2007). A comparison of allografting with autografting for newly diagnosed myeloma. *New England Journal of Medicine*, 356(11), 1110–1120. <https://doi.org/10.1056/NEJMoa065464>
- Falco, P., Bringhen, S., Avonto, I., Gay, F., Morabito, F., Boccadoro, M., & Palumbo, A. (2007). Melphalan and its role in the management of patients with multiple myeloma. *Expert Review of Anticancer Therapy*, 7(7), 945–957. <https://doi.org/10.1586/14737140.7.7.945>
- Palumbo, A., Ambrosini, M. T., Benevolo, G., Pregno, P., Pescosta, N., Callea, V., ... Boccadoro, M. (2007). Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. *Blood*, 109(7), 2767–2772. <https://doi.org/10.1182/blood-2006-08-042275>
- Bruno, B., Sorasio, R., Patriarca, F., Montefusco, V., Guidi, S., Busca, A., ... Boccadoro, M. (2007). Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma. *European Journal of Haematology*, 78(4), 330–337. <https://doi.org/10.1111/j.1600-0609.2007.00816.x>
- Palumbo, A., & Boccadoro, M. (2007). A new standard of care for elderly patients with myeloma. *Lancet*, 370(9594), 1191–1192. [https://doi.org/10.1016/S0140-6736\(07\)61522-0](https://doi.org/10.1016/S0140-6736(07)61522-0)
- Fiore, F., Castella, B., Nuschak, B., Bertieri, R., Mariani, S., Bruno, B., ... Massaia, M. (2007). Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. *Blood*, 110(3), 921–927. <https://doi.org/10.1182/blood-2006-09-044321>
- Offidani, M., Bringhen, S., Corvatta, L., Falco, P., Marconi, M., Avonto, I., ... Palumbo, A. (2007). Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: A case-matched study in advanced multiple myeloma. *European Journal of Haematology*, 78(4), 297–302. <https://doi.org/10.1111/j.1600-0609.2007.00823.x>
- Giaccone, L., Sorasio, R., Patriarca, F., Mattei, D., Montefusco, V., Peccatori, J., ... Bruno, B. (2007). Bortezomib after Allografting in Multiple Myeloma: Association between Neurotoxicity and Cyclosporine Treatment. *Biology of Blood and Marrow Transplantation*, 13(4), 497–499. <https://doi.org/10.1016/j.bbmt.2007.01.069>
- Richardson, P. G., Sonneveld, P., Schuster, M., Irwin, D., Stadtmauer, E., Facon, T., ... Anderson, K. C. (2007). Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial. *Blood*, 110(10), 3557–3560. <https://doi.org/10.1182/blood-2006-08-036947>
- Matta, G. M. E., Battaglio, S., Dibello, C., Napoli, P., Baldi, C., Ciccone, G., ... Massaia, M. (2007). Polyclonal immunoglobulin E levels are correlated with hemoglobin values and overall survival in patients with multiple myeloma. *Clinical Cancer Research*, 13(18), 5348–5354. <https://doi.org/10.1158/1078-0432.CCR-06-2819>
- Ricca, I., Rocci, A., Drandi, D., Francese, R., Compagno, M., Lobetti Bodoni, C., ... Ladetto, M. (2007). Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients. *Leukemia*, 21(4), 697–705. <https://doi.org/10.1038/sj.leu.2404544>
- Palumbo, A., Bringhen, S., Falco, P., Cavallo, F., Ambrosini, M. T., Avonto, I., ... Boccadoro, M. (2007). Time to first disease progression, but not $\beta 2$ -microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. *Cancer*, 110(4), 824–829. <https://doi.org/10.1002/cncr.22855>
- Vallet, S., Raje, N., Ishitsuka, K., Hideshima, T., Podar, K., Chhetri, S., ... Anderson, K. C. (2007). MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. *Blood*, 110(10), 3744–3752. <https://doi.org/10.1182/blood-2007-05-093294>
- Cavallo, F., Boccadoro, M., & Palumbo, A. (2007). Review of thalidomide in the treatment of newly diagnosed multiple myeloma. *Therapeutics and Clinical Risk Management*, 3(4), 543–552.
- Castagna, P., Redoglia, V., Stefanidou, E. M., Menato, G., Patriarca, A., Boccadoro, M., ... Massobrio, M. (2007). Phenotypic and functional analyses of peripheral blood T cells in women with recurrent spontaneous abortion in early stages of pregnancy. *Minerva Biotechnologica*, 19(3), 75–82.
- Rocci, A., Ricca, I., Dellacasa, C., Longoni, P., Compagno, M., Francese, R., ... Tarella, C. (2007). Long-term lymphoma survivors following high-dose chemotherapy and autograft: Evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir. *Experimental Hematology*, 35(4), 673–681. <https://doi.org/10.1016/j.exphem.2006.12.006>
- Palumbo, A., Falco, P., Corradini, P., Falcone, A., Di Raimondo, F., Giuliani, N., ... Petrucci, M. T. (2007). Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: A report from the GIMEMA - Italian Multiple Myeloma Network. *Journal of Clinical Oncology*, 25(28), 4459–4465. <https://doi.org/10.1200/JCO.2007.12.3463>

- Miguel, J. S., Bladé, J., Boccadoro, M., Cavenagh, J., Glasmacher, A., Jagannath, S., ... Ludwig, H. (2006). A practical update on the use of bortezomib in the management of multiple myeloma. *Oncologist*, 11(1), 51–61. <https://doi.org/10.1634/theoncologist.11-1-51>
- Ferrero, D., Pogliani, E. M., Rege-Cambrin, G., Fava, C., Mattioli, G., Dellacasa, C., ... Boccadoro, M. (2006). Corticosteroids can reverse severe imatinib-induced hepatotoxicity. *Haematologica*, 91(6 Suppl).
- Trojan, A., Tinguely, M., Vallet, S., Seifert, B., Jenni, B., Zippelius, A., ... Ladetto, M. (2006). Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma. *Swiss Medical Weekly*, 136(25–26), 400–403.
- Palumbo, A., Avonto, I., Bruno, B., Falcone, A., Scalzulli, P. R., Ambrosini, M. T., ... Boccadoro, M. (2006). Intermediate-dose melphalan (100 mg/m²)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma. *Clinical Lymphoma and Myeloma*, 6(6), 475–477. <https://doi.org/10.3816/CLM.2006.n.028>
- Musto, P., Falcone, A., Sanpaolo, G., Guglielmelli, T., Zambello, R., Balleari, E., ... Palumbo, A. (2006). Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide. *Leukemia Research*, 30(3), 283–285. <https://doi.org/10.1016/j.leukres.2005.06.027>
- Caravita, T., de Fabritiis, P., Palumbo, A., Amadori, S., & Boccadoro, M. (2006). Bortezomib: Efficacy comparisons in solid tumors and hematologic malignancies. *Nature Clinical Practice Oncology*, 3(7), 374–387. <https://doi.org/10.1038/ncponc0555>
- Palumbo, A., Avonto, I., Bruno, B., Ambrosini, M. T., Bringhen, S., Cavallo, F., ... Boccadoro, M. (2006). Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. *European Journal of Haematology*, 76(4), 273–277. <https://doi.org/10.1111/j.1600-0609.2005.00610.x>
- Mariani, S., Pantaleoni, F., Peola, S., Hwang, S. Y., Castella, B., Matta, G., ... Massaia, M. (2006). Distribution of $\gamma\delta$ T cells in patients with hematological malignancies. *Haematologica Reports*, 2(3), 32–34.
- Palumbo, A., Bringhen, S., Caravita, T., Merla, E., Capparella, V., Callea, V., ... Boccadoro, M. (2006). Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. *Lancet*, 367(9513), 825–831. [https://doi.org/10.1016/S0140-6736\(06\)68338-4](https://doi.org/10.1016/S0140-6736(06)68338-4)
- Bruno, B., Patriarca, F., Sorasio, R., Mattei, D., Montefusco, V., Peccatori, J., ... Corradini, P. (2006). Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. *Haematologica*, 91(6), 837–839.
- Palumbo, A., Rus, C., Zeldis, J. B., Rodeghiero, F., & Boccadoro, M. (2006). Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide [7]. *Journal of Thrombosis and Haemostasis*, 4(8), 1842–1845. <https://doi.org/10.1111/j.1538-7836.2006.02059.x>
- Bruno, B., Sorasio, R., Barozzi, P., Vieira, J., Omedè, P., Giaretta, F., ... Boccadoro, M. (2006). Kaposi's sarcoma triggered by endogenous HHV-8 reactivation after non-myeloablative allogeneic haematopoietic transplantation. *European Journal of Haematology*, 76(4), 342–347. <https://doi.org/10.1111/j.1600-0609.2005.00601.x>
- Massaia, M., Fiore, F., Castella, B., Pantaleoni, F., Mariani, S., Peola, S., ... Boccadoro, M. (2006). Unconventional properties of zoledronic acid. *Haematologica Reports*, 2(7), 106–108.
- Palumbo, A., Falco, P., Musto, P., Rossi, G., Giuliani, N., Morabito, F., ... Boccadoro, M. (2006). New treatment strategies for elderly myeloma patients. *Haematologica Reports*, 2(7), 113–114.
- Ladetto, M., Vallet, S., Benedetti, F., Vitolo, U., Martelli, M., Callea, V., ... Tarella, C. (2006). Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: Updated results of the multicenter consecutive GITMO trial. *Leukemia*, 20(10), 1840–1847. <https://doi.org/10.1038/sj.leu.2404346>
- Majolino, I., Ladetto, M., Locasciulli, A., Drandi, D., Benedetti, F., Gallamini, A., ... Tarella, C. (2006). High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission. *Medical Oncology*, 23(3), 359–368. <https://doi.org/10.1385/MO:23:3:359>
- Ladetto, M., Magni, M., Pagliano, G., De Marco, F., Drandi, D., Ricca, I., ... Tarella, C. (2006). Rituximab Induces Effective Clearance of Minimal Residual Disease in Molecular Relapses of Mantle Cell Lymphoma. *Biology of Blood and Marrow Transplantation*, 12(12), 1270–1276. <https://doi.org/10.1016/j.bbmt.2006.07.007>

- Bringhen, S., Avonto, I., Magarotto, V., Boccadoro, M., & Palumbo, A. (2006). Investigational treatments for multiple myeloma. *Expert Opinion on Investigational Drugs*, 15(12), 1565–1582. <https://doi.org/10.1517/13543784.15.12.1565>
- Conrotto, D., Carrozzo, M., Ubertalli, A. V., Gandolfo, S., Giaccone, L., Boccadoro, M., & Benedetto, B. (2006). Dramatic increase of tacrolimus plasma concentration during topical treatment for oral graft-versus-host disease [3]. *Transplantation*, 82(8), 1113–1115. <https://doi.org/10.1097/01.tp.0000232287.08903.1d>
- Garino, E., Berrino, M., Bertinetto, F., Caropreso, P., Chidichimo, R., Dametto, E., ... Amoroso, A. (2006). Identification of a new allele, HLA-DRB5*0113, through three different molecular biology techniques. *Tissue Antigens*, 67(5), 427–429. <https://doi.org/10.1111/j.1399-0039.2006.00588.x>
- Massaia, M., Boccadoro, M., & Bertieri, R. (2006). Cervo preclinical working conference introduction. *Haematologica Reports*, 2(3).
- Bruno, B., & Boccadoro, M. (2006). Emerging role for reduced intensity allotransplant in multiple myeloma. *Haematologica Reports*, 2(7), 111–112.
- Ladetto, M., Mantoan, B., De Marco, F., Drandi, D., Aguzzi, C., Astolfi, M., ... Tarella, C. (2006). Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations. *Experimental Hematology*, 34(12), 1680–1686. <https://doi.org/10.1016/j.exphem.2006.08.008>
- Ladetto, M., Vallet, S., Trojan, A., Dell'Aquila, M., Monitillo, L., Rosato, R., ... Boccadoro, M. (2005). Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. *Blood*, 105(12), 4784–4791. <https://doi.org/10.1182/blood-2004-11-4201>
- Mariani, S., Muraro, M., Pantaleoni, F., Fiore, F., Nuschak, B., Peola, S., ... Massaia, M. (2005). Effector $\gamma\delta$ T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. *Leukemia*, 19(4), 664–670. <https://doi.org/10.1038/sj.leu.2403693>
- Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., ... Anderson, K. C. (2005). Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. *New England Journal of Medicine*, 352(24), 2487–2498. <https://doi.org/10.1056/NEJMoa043445>
- Fiore, F., Nuschak, B., Peola, S., Mariani, S., Muraro, M., Foglietta, M., ... Massaia, M. (2005). Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells. *European Journal of Immunology*, 35(4), 1155–1163. <https://doi.org/10.1002/eji.200425093>
- Compagno, M., Mantoan, B., Astolfi, M., Boccadoro, M., & Ladetto, M. (2005). Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in myeloma. *Methods in Molecular Medicine*, 113, 145–163.
- Boccadoro, M., Morgan, G., & Cavenagh, J. (2005). Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. *Cancer Cell International*, 5. <https://doi.org/10.1186/1475-2867-5-18>
- Boccadoro, M., Blade, J., Attal, M., & Palumbo, A. (2005). The future role of thalidomide in multiple myeloma. *Acta Haematologica*, 114(SUPPL. 1), 18–22. <https://doi.org/10.1159/000087040>
- Bruno, B., Giaccone, L., Rotta, M., Anderson, K., & Boccadoro, M. (2005). Novel targeted drugs for the treatment of multiple myeloma: From bench to bedside. *Leukemia*, 19(10), 1729–1738. <https://doi.org/10.1038/sj.leu.2403905>
- Greipp, P. R., Miguel, J. S., Dune, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., ... Westin, J. (2005). International staging system for multiple myeloma. *Journal of Clinical Oncology*, 23(15), 3412–3420. <https://doi.org/10.1200/JCO.2005.04.242>
- Palumbo, A., Bertola, A., Musto, P., Caravita, T., Callea, V., Nunzi, M., ... Boccadoro, M. (2005). Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. *Cancer*, 104(7), 1428–1433. <https://doi.org/10.1002/cncr.21342>
- Palumbo, A., Falco, P., Ambrosini, M. T., Petrucci, M. T., Musto, P., Caravita, T., ... Boccadoro, M. (2005). Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant. *European Journal of Haematology*, 75(5), 391–395. <https://doi.org/10.1111/j.1600-0609.2005.00533.x>
- Palumbo, A., Petrucci, M. T., Lauta, V. M., Musto, P., Caravita, T., Barbui, A. M., ... Boccadoro, M. (2005). Correlation between fatigue and hemoglobin level in multiple myeloma patients: Results of a cross-sectional study. *Haematologica*, 90(6), 858–860.

- Barosi, G., Boccadoro, M., Cavo, M., Corradini, P., Marchetti, M., Massaia, M., ... Tura, S. (2004). Management of multiple myeloma and related-disorders: Guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). *Haematologica*, 89(6), 717–741.
- Palumbo, A., Bringhen, S., Petrucci, M. T., Musto, P., Rossini, F., Nunzi, M., ... Boccadoro, M. (2004). Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: Results of a randomized controlled trial. *Blood*, 104(10), 3052–3057. <https://doi.org/10.1182/blood-2004-02-0408>
- Levis, A., Pietrasanta, D., Godio, L., Vitolo, U., Ciravegna, G., Di Vito, F., ... Gallo, E. (2004). A large-scale study of bone marrow involvement in patients with Hodgkin's lymphoma. *Clinical Lymphoma*, 5(1), 50–55. <https://doi.org/10.3816/CLM.2004.n.010>
- Ladetto, M., Compagno, M., Ricca, I., Pagano, M., Rocci, A., Astolfi, M., ... Tarella, C. (2004). Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders. *Blood*, 103(12), 4644–4649. <https://doi.org/10.1182/blood-2003-12-4412>
- Bruno, B., Rotta, M., Giaccone, L., Massaia, M., Bertola, A., Palumbo, A., & Boccadoro, M. (2004). New drugs for treatment of multiple myeloma. *Lancet Oncology*, 5(7), 430–442. [https://doi.org/10.1016/S1470-2045\(04\)01511-6](https://doi.org/10.1016/S1470-2045(04)01511-6)
- Palumbo, A., Bringhen, S., Bertola, A., Cavallo, F., Falco, P., Massaia, M., ... Boccadoro, M. (2004). Multiple myeloma: Comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m²). *Leukemia*, 18(1), 133–138. <https://doi.org/10.1038/sj.leu.2403196>
- Levis, A., Anselmo, A. P., Ambrosetti, A., Adamo, F., Bertini, M., Cavalieri, E., ... Mandelli, F. (2004). VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. *Annals of Oncology*, 15(1), 123–128. <https://doi.org/10.1093/annonc/mdh012>
- Corradini, P., Ladetto, M., Zallio, F., Astolfi, M., Rizzo, E., Sametti, S., ... Tarella, C. (2004). Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: Evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. *Journal of Clinical Oncology*, 22(8), 1460–1468. <https://doi.org/10.1200/JCO.2004.10.054>
- Corradini, P., Doderio, A., Zallio, F., Caracciolo, D., Casini, M., Bregni, M., ... Tarella, C. (2004). Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. *Journal of Clinical Oncology*, 22(11), 2172–2176. <https://doi.org/10.1200/JCO.2004.12.050>
- Isoardo, G., Bergui, M., Durelli, L., Barbero, P., Boccadoro, M., Bertola, A., ... Cocito, D. (2004). Thalidomide neuropathy: Clinical, electrophysiological and neuroradiological features. *Acta Neurologica Scandinavica*, 109(3), 188–193. <https://doi.org/10.1034/j.1600-0404.2003.00203.x>
- Coscia, M., Mariani, S., Battaglio, S., Di Bello, C., Fiore, F., Foglietta, M., ... Massaia, M. (2004). Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. *Leukemia*, 18(1), 139–145. <https://doi.org/10.1038/sj.leu.2403181>
- Garino, E., Berrino, M., Mazzola, G., Boccadoro, M., Bruno, B., Bertinetto, F., ... Dall'Omo, A. M. (2004). Identification of a new HLA-DRB1 allele in three members of an Italian family. *Tissue Antigens*, 64(2), 210–212. <https://doi.org/10.1111/j.1399-0039.2004.00262.x>
- Durie, B. G. M., Kyle, R. A., Belch, A., Bensinger, W., Blade, J., Boccadoro, M., ... Van Ness, B. (2004). Erratum: Myeloma management guidelines: A consensus report from the scientific advisors of the international myeloma foundation (The Hematology Journal (2003) vol, 4 (379-398) 10.1038/sj.thj.6200312). *Hematology Journal*, 5(3), 285. <https://doi.org/10.1038/sj.thj.6200402>
- Falco, P., Bertola, A., Bringhen, S., Cavallo, F., Boccadoro, M., & Palumbo, A. (2004). Successful management of immune thrombocytopenic purpura with thalidomide in a patient with multiple myeloma [3]. *Hematology Journal*, 5(5), 456–457. <https://doi.org/10.1038/sj.thj.6200404>
- Palumbo, A., Bertola, A., Falco, P., Rosato, R., Cavallo, F., Giaccone, L., ... Boccadoro, M. (2004). Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. *Hematology Journal*, 5(4), 318–324. <https://doi.org/10.1038/sj.thj.6200403>
- Ferrero, D., Campa, E., Dellacasa, C., Campana, S., Folli, C., & Boccadoro, M. (2004). Differentiating agents + low-dose chemotherapy in the management of old/poor prognosis patients with acute myeloid leukemia or myelodysplastic syndrome. *Haematologica*, 89(5), 619–620.
- Rus, C., Bazzan, M., Palumbo, A., Bringhen, S., & Boccadoro, M. (2004). Thalidomide in front line treatment in multiple myeloma: Serious risk of venous thromboembolism and evidence for thromboprophylaxis [10].

Journal of Thrombosis and Haemostasis, 2(11), 2063–2065. <https://doi.org/10.1111/j.1538-7836.2004.00931.x>

Bonello, L., Voena, C., Ladetto, M., Boccadoro, M., Palestro, G., Inghirami, G., & Chiarle, R. (2003). BRAF gene is not mutated in plasma cell leukemia and multiple myeloma [4]. *Leukemia*, 17(11), 2238–2240. <https://doi.org/10.1038/sj.leu.2403116>

Voena, C., Malnati, M., Majolino, I., Fagà, G., Montefusco, V., Farina, L., ... Corradini, P. (2003). Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation. *Bone Marrow Transplantation*, 32(8), 791–793. <https://doi.org/10.1038/sj.bmt.1704207>

Rosti, G., Bonifazi, F., Trabacchi, E., de Vivo, A., Bassi, S., Martinelli, G., ... Bergonzi, C. (2003). A phase II study of α -interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia. *Leukemia*, 17(3), 554–559. <https://doi.org/10.1038/sj.leu.2402850>

Ladetto, M., Drandi, D., Compagno, M., Astolfi, M., Volpato, F., Voena, C., ... Tarella, C. (2003). PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapy. *Journal of Clinical Oncology*, 21(7), 1398–1403. <https://doi.org/10.1200/JCO.2003.07.070>

Gorin, N. C., Labopin, M., Rocha, V., Arcese, W., Beksac, M., Gluckman, E., ... Zoumbos, N. C. (2003). Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow. *Blood*, 102(8), 3043–3051. <https://doi.org/10.1182/blood-2003-03-0665>

Kyle, R. A., Child, J. A., Anderson, K., Barlogie, B., Bataille, R., Bensinger, W., ... Wheatley, K. (2003). Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. *British Journal of Haematology*, 121(5), 749–757. <https://doi.org/10.1046/j.1365-2141.2003.04355.x>

Tarella, C., Cuttica, A., Vitolo, U., Liberati, M., Di Nicola, M., Cortelazzo, S., ... Levis, A. (2003). High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: A multicenter study of the Intergruppo Italiano Linfomi showing prolonged disease free survival in patients. *Cancer*, 97(11), 2748–2759. <https://doi.org/10.1002/cncr.11414>

Majolino, I., Corradini, P., Scimè, R., Falda, M., Bosi, A., Tarella, C., ... Pileri, A. (2003). High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors. *Bone Marrow Transplantation*, 31(9), 767–773. <https://doi.org/10.1038/sj.bmt.1703924>

Corradini, P., Cavo, M., Lokhorst, H., Martinelli, G., Terragna, C., Majolino, I., ... Gahrton, G. (2003). Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. *Blood*, 102(5), 1927–1929. <https://doi.org/10.1182/blood-2003-01-0189>

Ladetto, M., Mantoan, B., Ricca, I., Astolfi, M., Drandi, D., Compagno, M., ... Tarella, C. (2003). Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone. *Experimental Hematology*, 31(9), 784–788. [https://doi.org/10.1016/S0301-472X\(03\)00191-7](https://doi.org/10.1016/S0301-472X(03)00191-7)

Durie, B. G. M., Kyle, R. A., Belch, A., Bensinger, W., Blade, J., Boccadoro, M., ... Van Ness, B. (2003). Myeloma management guidelines: A consensus report from the Scientific Advisors of the International Myeloma Foundation. *Hematology Journal*, 4(6), 379–398. <https://doi.org/10.1038/sj.thj.6200312>

Cuttica, A., Zallio, F., Ladetto, M., Di Nicola, M., Caracciolo, D., Magni, M., ... Tarella, C. (2003). Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting: Evidence of marked differences in outcome between patients with age-adjusted international prognostic index scores 2 and 3. *Cancer*, 98(5), 983–992. <https://doi.org/10.1002/cncr.11610>

Boccadoro, M., Palumbo, A., Bringhen, S., Merletti, F., Ciccone, G., Richiardi, L., ... Pileri, A. (2002). Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. *Haematologica*, 87(8), 846–850.

Boccadoro, M., & Palumbo, A. (2002). New developments and treatment in multiple myeloma: New drugs in the treatment of multiple myeloma. *Annals of Oncology*, 13(SUPPL. 4), 55–58. <https://doi.org/10.1093/annonc/mdf639>

Voena, C., Locatelli, G., Castellino, C., Omedè, P., Ladetto, M., Zappone, E., ... Corradini, P. (2002). Qualitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after

- positive selection of CD34⁺ cells with small- and large-scale Miltenyi cell sorting system. *British Journal of Haematology*, 117(3), 642–645. <https://doi.org/10.1046/j.1365-2141.2002.03448.x>
- Ladetto, M., Omedè, P., Sametti, S., Donovan, J. W., Astolfi, M., Drandi, D., ... Boccadoro, M. (2002). Real-time polymerase chain reaction in multiple myeloma: Quantitative analysis of tumor contamination of stem cell harvests. *Experimental Hematology*, 30(6), 529–536. [https://doi.org/10.1016/S0301-472X\(02\)00794-4](https://doi.org/10.1016/S0301-472X(02)00794-4)
- Busca, A., Bruno, B., Boccadoro, M., Locatelli, F., & Falda, M. (2002). Allogenic stem cell transplantation following non-myeloablative conditioning regimens as adoptive immunotherapy in patients with hematological malignancies. *Medical Science Monitor*, 8(10).
- Mariani, S., Coscia, M., Even, J., Peola, S., Foglietta, M., Boccadoro, M., ... Massaia, M. (2001). Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion. *British Journal of Haematology*, 113(4), 1051–1059. <https://doi.org/10.1046/j.1365-2141.2001.02871.x>
- Tarella, C., Cuttica, A., Caracciolo, D., Zallio, F., Ricca, I., Bergui, L., ... Pileri, A. (2001). High-dose sequential (HDS) chemotherapy for high-risk non-Hodgkin's lymphoma: Long-term analysis and future developments. *Annals of Hematology, Supplement*, 80(3), B123–B126.
- Ladetto, M., Zallio, F., Vallet, S., Ricca, I., Cuttica, A., Caracciolo, D., ... Tarella, C. (2001). Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. *Leukemia*, 15(12), 1941–1949. <https://doi.org/10.1038/sj.leu.2402302>
- Palumbo, A., Giaccone, L., Bertola, A., Pregno, P., Bringhen, S., Rus, C., ... Boccadoro, M. (2001). Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. *Haematologica*, 86(4), 399–403.
- Palumbo, A., Triolo, S., Baldini, L., Callea, V., Capaldi, A., De Stefano, V., ... Boccadoro, M. (2000). Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients. *Haematologica*, 85(5), 508–513.
- Besostri, B., Beggiato, E., Bianchi, A., Mariani, S., Coscia, M., Peola, S., ... Massaia, M. (2000). Increased expression of non-functional killer inhibitory receptor CD94 in CD8⁺ cells of myeloma patients. *British Journal of Haematology*, 109(1), 46–53. <https://doi.org/10.1046/j.1365-2141.2000.01981.x>
- Ladetto, M., Sametti, P. O. S., Donovan, J. W., Astolfi, M., Giaccone, L., Giaretta, F., ... Boccadoro, M. (2000). Real time quantitative pcr shows that peripheral blood stem cell (pbpc) harvests are significantly less contaminated than bone marrow (bm) in multiple myeloma patients (mm). *Blood*, 96(11 PART I).
- Ornede, P., Giaretta, F., Palumbo, A., Ladetto, M., Bruno, B., Gilestro, M., ... Boccadoro, M. (2000). Multiple myeloma: Different phenotypic characteristics are shown by plasma cells from leukapheresis and bone marrow. *Blood*, 96(11 PART I).
- Palumbo, A., Giaccone, L., Bertola, A., Bringhen, S., Rus, C., Triolo, S., ... Boccadoro, M. (2000). Thalidomide and dexamethasone as salvage therapy for refractory and relapsed myeloma. *Blood*, 96(11 PART II).
- Boccadoro, M., Omedè, P., Dominietto, A., Palumbo, A., Bringhen, S., Giaretta, F., ... Pileri, A. (2000). Multiple myeloma: The number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support. *Bone Marrow Transplantation*, 25(1), 25–29. <https://doi.org/10.1038/sj.bmt.1702085>
- Corradini, P., Voena, C., Tarella, C., Astolfi, M., Ladetto, M., Palumbo, A., ... Pileri, A. (1999). Molecular and clinical remissions in multiple myeloma: Role of autologous and allogeneic transplantation of hematopoietic cells. *Journal of Clinical Oncology*, 17(1), 208–215.
- Massaia, M., Borriore, P., Battaglio, S., Mariani, S., Beggiato, E., Napoli, P., ... Pileri, A. (1999). Idiotypic vaccination in human myeloma: Generation of tumor-specific immune responses after high-dose chemotherapy. *Blood*, 94(2), 673–683.
- Boccadoro, M., Tarella, C., Palumbo, A., Argentino, C., Triolo, S., Dominietto, A., ... Pileri, A. (1999). An analysis of which subgroups of multiple myeloma patients, divided according to β_2 -microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy. *Haematologica*, 84(10), 905–910.
- Palumbo, A., Triolo, S., Argentino, C., Bringhen, S., Dominietto, A., Rus, C., ... Boccadoro, M. (1999). Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. *Blood*, 94(4), 1248–1253.

- Massaia, M., Mariani, S., Battaglio, S., Beggiato, E., Besostri, B., Borriore, P., ... Pileri, A. (1998). Idiotypic reactive T cells. *Cancer Research Therapy and Control*, 6(1-4), 171-174.
- Corradini, P., Tarella, C., Voena, C., Astolfi, M., Ladetto, M., Palumbo, A., ... Boccadoro, M. (1998). PCR-based monitoring of residual myeloma cells in patients undergoing high-dose chemotherapy. *Cancer Research Therapy and Control*, 6(1-4), 293-294.
- Pileri, A., Palumbo, A., Triolo, S., Dominietto, A., Argentino, C., Brighen, S., ... Boccadoro, M. (1998). Intensified therapy with stem cell support for patients over age 60. *Cancer Research Therapy and Control*, 6(1-4), 259-261.
- Majolino, I., Corradini, P., Scimé, R., Santoro, A., Tarella, C., Cavallaro, A. M., ... Pileri, A. (1998). Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma. *Bone Marrow Transplantation*, 22(5), 449-455. <https://doi.org/10.1038/sj.bmt.1701362>
- Boccadoro, M., Palumbo, A., Tarella, C., Argentino, C., Dominietto, A., Triolo, S., ... Pileri, A. (1998). Prognostic factors and high dose chemotherapy. *Cancer Research Therapy and Control*, 6(1-4), 103-104.
- Palumbo, A., Pileri, A., Triolo, S., Omedè, P., Bruno, B., Ciravegna, G., ... Boccadoro, M. (1997). Multicyclic, dose-intensive chemotherapy supported by hemopoietic progenitors in refractory myeloma patients. *Bone Marrow Transplantation*, 19(1), 23-29. <https://doi.org/10.1038/sj.bmt.1700599>
- Voena, C., Ladetto, M., Astolfi, M., Provan, D., Gribben, J. G., Boccadoro, M., ... Corradini, P. (1997). A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. *Leukemia*, 11(10), 1793-1798. <https://doi.org/10.1038/sj.leu.2400801>
- Boccadoro, M., Palumbo, A., Argentino, C., Dominietto, A., Frieri, R., Avvisati, G., ... Pileri, A. (1997). Conventional induction treatments do not influence overall survival in multiple myeloma. *British Journal of Haematology*, 96(2), 333-337. <https://doi.org/10.1046/j.1365-2141.1997.d01-2041.x>
- Iida, S., Rao, P. H., Butler, M., Corradini, P., Boccadoro, M., Klein, B., ... Dalla-Favera, R. (1997). Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. *Nature Genetics*, 17(2), 230. <https://doi.org/10.1038/ng1097-226>
- Bianchi, A., Mariani, S., Beggiato, E., Borriore, P., Peola, S., Boccadoro, M., ... Massaia, M. (1997). Distribution of T-cell signalling molecules in human myeloma. *British Journal of Haematology*, 97(4), 815-820.
- Boccadoro, M., & Pileri, A. (1997). Diagnosis, prognosis, and standard treatment of multiple myeloma. *Hematology/Oncology Clinics of North America*, 11(1), 111-131. [https://doi.org/10.1016/S0889-8588\(05\)70418-4](https://doi.org/10.1016/S0889-8588(05)70418-4)
- Triolo, R., Omedè, P., Giaretta, F., Ravaglia, R., Battaglio, S., Palumbo, A., ... Boccadoro, M. (1997). Cytofluorimetric evaluation of plasma cell proliferative activity in monoclonal gammopathies. *European Journal of Histochemistry : EJH*, 41 Suppl 2, 57-58.
- Omedè, P., Tarella, C., Palumbo, A., Argentino, C., Caracciolo, D., Corradini, P., ... Boccadoro, M. (1997). Multiple myeloma: Reduced plasma cell contamination in peripheral blood progenitor cell collections performed after repeated high-dose chemotherapy courses. *British Journal of Haematology*, 99(3), 685-691.
- Marmont, F., Pich, A., Chiusa, L., Locatelli, F., Falda, M., Boccadoro, M., & Resegotti, L. (1996). Correlation between argyrophilic nucleolar organizer region counts and labelling index in multiple myeloma. *European Journal of Haematology*, 56(1-2), 39-44.
- Battaglio, S., Napoli, P., Beggiato, E., Borriore, P., Ciaiolo, C., Peola, S., ... Massaia, M. (1996). Development of vaccines against autologous tumor-derived idiotypes in human myeloma: Rationale and preparation. *Minerva Biotechnologica*, 8(1), 1-8.
- Pileri, A., Palumbo, A., & Boccadoro, M. (1996). Current therapeutic options for multiple myeloma. *Haematologica*, 81(4), 291-294.
- Napoli, P., Battaglio, S., Ciaiolo, C., & Boccadoro, M. (1995). Case report: Mixed cryoglobulinemia IgMk-IgMλ in a patient with double monoclonal component | CRIOGLOBULINEMIA MISTA IGMK-IGMλ CON DOPPIA COMPONENTE MONOCLONALE SIERICA. DESCRIZIONE DI UN CASO. *Minerva Medica*, 86(5), 223-226.
- Boccadoro, M., & Pileri, A. (1995). 1Plasma cell dyscrasias: classification, clinical and laboratory characteristics, and differential diagnosis. *Bailliere's Clinical Haematology*, 8(4), 705-719. [https://doi.org/10.1016/S0950-3536\(05\)80255-0](https://doi.org/10.1016/S0950-3536(05)80255-0)
- Palumbo, A., Battaglio, S., Napoli, P., Bruno, B., Omedè, P., Boccadoro, M., & Pileri, A. (1995). Retinoic acid inhibits the growth of human myeloma cells in vitro. *British Journal of Haematology*, 89(3), 555-560. <https://doi.org/10.1111/j.1365-2141.1995.tb08363.x>

- Massaia, M., Borriore, P., Attisano, C., Barral, P., Beggiato, E., Montacchini, L., ... Pileri, A. (1995). Dysregulated Fas and bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients. *Blood*, 85(12), 3679–3687.
- BIANCHI, A., MONTACCHINI, L., BARRAL, P., BORRIONE, P., ATTILIANO, C., ORSINI, E., ... MASSAIA, M. (1995). CD3-induced T-cell activation in the bone marrow of myeloma patients: major role of CD4⁺ cells. *British Journal of Haematology*, 90(3), 625–632. <https://doi.org/10.1111/j.1365-2141.1995.tb05594.x>
- Pellat-Deccunynk, C., Amiot, M., Bataille, R., Van Riet, I., Van Camp, B., Omede, P., & Boccadoro, M. (1995). Human myeloma cell lines as a tool for studying the biology of multiple myeloma: A reappraisal 18 years after [5]. *Blood*, 86(10), 4001–4002.
- Battaglio, S., Napoli, P., Bruno, B., & Boccadoro, M. (1995). Kappa/Lambda ratio: A valid tool in the monitoring of multiple myeloma. *Giornale Italiano Di Chimica Clinica*, 20(5), 263–269.
- Corradini, P., Voena, C., Astolfi, M., Ladetto, M., Tarella, C., Boccadoro, M., & Pileri, A. (1995). High-dose sequential chemoradiotherapy in multiple myeloma: Residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. *Blood*, 85(6), 1596–1602.
- Palumbo, A., Bruno, B., Boccadoro, M., & Pileri, A. (1995). Interferon- γ in multiple myeloma. *Leukemia and Lymphoma*, 18(3–4), 215–219. <https://doi.org/10.3109/10428199509059610>
- Attisano, C., Bianchi, A., Montacchini, L., Carlesso, N., Peola, S., Bruno, B., ... Massaia, M. (1994). Generation of anti-tumour activity by OKT3-stimulation in multiple myeloma: In vitro inhibition of autologous haemopoiesis. *British Journal of Haematology*, 87(3), 494–502. <https://doi.org/10.1111/j.1365-2141.1994.tb08303.x>
- Dianzani, U., Omedè, P., Marmont, F., DiFranco, D., Fusaro, A., Bragardo, M., ... Pileri, A. (1994). Expansion of T cells expressing low CD4 or CD8 levels in B-cell chronic lymphocytic leukemia: Correlation with disease status and neoplastic phenotype. *Blood*, 83(8), 2198–2205.
- Corradini, P., Inghirami, G., Astolfi, M., Ladetto, M., Voena, C., Ballerini, P., ... Dalla-Favera, R. (1994). Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. *Leukemia*, 8(5), 758–767.
- Palumbo, A., Boccadoro, M., Bruno, B., Triolo, S., & Pileri, A. (1994). Cyclophosphamide (3.6 g/m²) therapy with G-CSF support for resistant myeloma. *Haematologica*, 79(6), 513–518.
- Pich, A., Chiusa, L., Boccadoro, M., & Marmont, F. (1994). AgNORs and myeloma prognosis. *Leukemia and Lymphoma*, 12(5–6), 383–394. <https://doi.org/10.3109/10428199409073779>
- Gianni, A. M., Tarella, C., Bregni, M., Siena, S., Lombardi, F., Gandola, L., ... Pileri, A. (1994). High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma. *Journal of Clinical Oncology*, 12(3), 503–509. <https://doi.org/10.1200/JCO.1994.12.3.503>
- Palumbo, A., Battaglio, S., Napoli, P., Omede, P., Fusaro, A., Bruno, B., ... Pileri, A. (1994). Recombinant interferon- γ inhibits the in vitro proliferation of human myeloma cells. *British Journal of Haematology*, 86(4), 726–732. <https://doi.org/10.1111/j.1365-2141.1994.tb04821.x>
- Palumbo, A., Bruno, B., Triolo, S., Boccadoro, M., & Pileri, A. (1994). Recombinant interferon- γ in a patient with multiple myeloma. *European Journal of Cancer*, 30(11), 1731. [https://doi.org/10.1016/0959-8049\(94\)90605-X](https://doi.org/10.1016/0959-8049(94)90605-X)
- Kyle, R. A., Durie, B. G., Boccadoro, M., & Pavlovsky, S. (1994). Myeloma and related disorders. *Revista de Investigacion Clinica, Suppl*, 46–51.
- Corradini, P., Ladetto, M., Inghirami, G., Boccadoro, M., & Pileri, A. (1994). N- and k-ras oncogenes in plasma cell dyscrasias. *Leukemia and Lymphoma*, 15(1–2), 17–20. <https://doi.org/10.3109/10428199409051673>
- Corradini, P., Voena, C., Omedè, P., Astolfi, M., Boccadoro, M., Dalla-Favera, R., & Pileri, A. (1993). Detection of circulating tumor cells in multiple myeloma by a PCR-based method. *Leukemia*, 7(11), 1879–1882.
- Corradini, P., Ferrero, D., Voena, C., Ladetto, M., Boccadoro, M., & Pileri, A. (1993). THE MUTATION OF N-RAS ONCOGENE DOES NOT INVOLVE MYELOID AND ERYTHROID LINEAGES IN A CASE OF MULTIPLE MYELOMA. *British Journal of Haematology*, 83(4), 672–673. <https://doi.org/10.1111/j.1365-2141.1993.tb04711.x>
- Tarella, C., Boccadoro, M., Omede, P., Bondesan, P., Caracciolo, D., Frieri, R., ... Pileri, A. (1993). Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilization in multiple myeloma. *Bone Marrow Transplantation*, 11(4), 271–277.

- Corradini, P., Boccadoro, M., Voena, C., & Pileri, A. (1993). Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C μ sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas. *Journal of Experimental Medicine*, 178(3), 1091–1096. <https://doi.org/10.1084/jem.178.3.1091>
- Corradini, P., Ladetto, M., Voena, C., Palumbo, A., Inghirami, G., Knowles, D. M., ... Pileri, A. (1993). Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. *Blood*, 81(10), 2708–2713.
- Palumbo, A., Boccadoro, M., Garino, L. A., Gallone, G., Frieri, R., & Pileri, A. (1993). Interferon plus glucocorticoids as intensified maintenance therapy prolongs tumor control in relapsed myeloma. *Acta Haematologica*, 90(2), 71–76. <https://doi.org/10.1159/000204379>
- Omedè, P., Boccadoro, M., Fusaro, A., Gallone, G., & Pileri, A. (1993). Multiple myeloma: 'early' plasma cell phenotype identifies patients with aggressive biological and clinical characteristics. *British Journal of Haematology*, 85(3), 504–513. <https://doi.org/10.1111/j.1365-2141.1993.tb03340.x>
- Pileri, A., Palumbo, A., & Boccadoro, M. (1993). Multiple myeloma: A tailored therapy for elderly patients. *Hematological Oncology*, 11(SUPPL. 1), 67–72.
- Massaia, M., Attisano, C., Peola, S., Montacchini, L., Omedè, P., Corradini, P., ... Pileri, A. (1993). Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells. *Blood*, 82(6), 1787–1797.
- Boccadoro, M., Gallone, G., Frieri, R., Pileri, A., Bataille, R., Klein, B., ... Kyle, R. A. (1993). Plasma cell labeling index, β -microglobulin, and C-reactive protein: What is the best combination for myeloma prognosis? [5]. *Blood*, 82(11), 3507–3508.
- Boccadoro, M., & Pileri, A. (1993). Biology and treatment of multiple myeloma. *FORUM - Trends in Experimental and Clinical Medicine*, 3(3), 269–275.
- Tarella, C., Omedè, P., Boccadoro, M., Palumbo, A., Battaglio, S., & Pileri, A. (1992). Early disappearance of murine plasmacytoma stem cells in long-term bone marrow culture. *Leukemia Research*, 16(8), 743–750. [https://doi.org/10.1016/0145-2126\(92\)90152-W](https://doi.org/10.1016/0145-2126(92)90152-W)
- Palumbo, A., Battaglio, S., Astolfi, M., Frieri, R., Boccadoro, M., & Pileri, A. (1992). Multiple independent immunoglobulin class-switch recombinations occurring within the same clone in myeloma. *British Journal of Haematology*, 82(4), 676–680. <https://doi.org/10.1111/j.1365-2141.1992.tb06943.x>
- Palumbo, A., Boccadoro, M., Garino, L. A., Gallone, G., Frieri, R., & Pileri, A. (1992). Multiple myeloma: Intensified maintenance therapy with recombinant interferon- α -2b plus glucocorticoids. *European Journal of Haematology*, 49(2), 93–97. <https://doi.org/10.1111/j.1600-0609.1992.tb00037.x>
- Rollino, C., Roccatello, D., Mazzucco, G., Boccadoro, M., Massaia, M., Battaglio, S., ... Piccoli, G. (1992). Immunologic characteristics of fibrillary glomerulonephritis. *Nephron*, 62(4), 399–403.
- Reibnegger, G., Wachter, H., Krainer, M., Ludwig, H., Herold, M., Huber, H., ... Pileri, A. (1992). Hyperreactive cellular immunity in multiple myeloma [3]. *Blood*, 79(8), 2174–2176.
- Massaia, M., Bianchi, A., Attisano, C., Dianzani, U., Boccadoro, M., & Pileri, A. (1992). Cyclosporin A and dipyridamole: An effective combination against the generation of cytotoxic T lymphocytes (CTL). *Pharmacological Research*, 26(SUPPL. 2), 12–13. [https://doi.org/10.1016/1043-6618\(92\)90576-W](https://doi.org/10.1016/1043-6618(92)90576-W)
- Bataille, R., Boccadoro, M., Klein, B., Durie, B., & Pileri, A. (1992). C-Reactive Protein and β -2 microglobulin produce a simple and powerful myeloma staging system. *Blood*, 80(3), 733–737.
- Amadori, S., Bernasconi, C., Boccadoro, M., Giustolisi, R., & Gobbi, M. (1992). Academic promotion in Italy [1]. *Nature*, 355(6361), 581. <https://doi.org/10.1038/355581a0>
- Boccadoro, M., & Pileri, A. (1992). Standard chemotherapy for myelomatosis: An area of great controversy. *Hematology/Oncology Clinics of North America*, 6(2), 371–382.
- Corradini, P., Boccadoro, M., Pileri, A., Trainor, K. J., Brisco, M. J., Wan, J.-H., ... Morley, A. A. (1992). Analysis of immunoglobulin heavy chain gene rearrangement using the polymerase chain reaction [2]. *Blood*, 79(1), 291–292.
- Bianchi, A., Omedè, P., Attisano, C., Camponi, A., Dianzani, U., Boccadoro, M., ... Massaia, M. (1991). Phenotypic and functional analysis of peripheral blood lymphocytes during interferon-alpha 2b therapy in multiple myeloma patients with low tumor mass. *Haematologica*, 76(5), 383–388.
- Palumbo, A. P., Corradini, P., Battaglio, S., Omedè, P., Coda, R., Boccadoro, M., & Pileri, A. (1991). Dual rearrangement of immunoglobulin and T-cell receptor gene in a case of T-cell hairy-cell leukemia. *European Journal of Haematology*, 46(2), 71–76. <https://doi.org/10.1111/j.1600-0609.1991.tb00525.x>

- Boccadoro, M., Battaglio, S., Omede, P., Palumbo, A. P., Fusaro, A., Frieri, R., ... Pileri, A. (1991). Increased serum neopterin concentration as indicator of disease severity and poor survival in multiple myeloma. *European Journal of Haematology*, 47(4), 305–309. <https://doi.org/10.1111/j.1600-0609.1991.tb01576.x>
- Boccadoro, M., Battaglio, S., Dianzani, U., Frieri, R., Gallone, G., Massaia, M., ... Pileri, A. (1991). Multiple myeloma: The mechanisms of neoplastic proliferation and progression and their clinical implications | IL MIELOMA MULTIPLO. MECCANISMI DI PROLIFERAZIONE E PROGRESSIONE NEOPLASTICA E LORO IMPLICAZIONI CLINICHE. *Haematologica*, 76(SUPPL. 3), 100–106.
- Massaia, M., Bianchi, A., Attisano, C., Dianzani, U., Boccadoro, M., & Pileri, A. (1991). Dipyridamole in vitro suppresses the generation of T-cell cytotoxic functions: Synergistic activity with cyclosporine. *European Journal of Haematology*, 46(1), 6–10. <https://doi.org/10.1111/j.1600-0609.1991.tb00506.x>
- Boccadoro, M., Marmont, F., Tribalto, M., Avvisati, G., Andriani, A., Barbui, T., ... Neretto, G. (1991). Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. *Journal of Clinical Oncology*, 9(3), 444–448. <https://doi.org/10.1200/JCO.1991.9.3.444>
- Redoglia, V., Boccadoro, M., Battaglio, S., Dianzani, U., Massaia, M., & Pileri, A. (1990). Multiple myeloma: Altered CD4/CD8 ratio in bone marrow. *Haematologica*, 75(2), 129–131.
- Omede, P., Boccadoro, M., Gallone, G., Frieri, R., Battaglio, S., Redoglia, V., & Pileri, A. (1990). Multiple myeloma: Increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival. *Blood*, 76(7), 1375–1379.
- Mandelli, F., Avvisati, G., Amadori, S., Boccadoro, M., Gernone, A., Lauti, V. M., ... Pileri, A. (1990). Maintenance Treatment with Recombinant Interferon Alfa-2b in Patients with Multiple Myeloma Responding to Conventional Induction Chemotherapy. *New England Journal of Medicine*, 322(20), 1430–1434. <https://doi.org/10.1056/NEJM199005173222005>
- Boccadoro, M., Avvisati, G., Cantonetti, M., Cavo-Comotti, B. M., Frieri, R., Gallamini, A., ... Pileri, A. (1990). Therapy of multiple myeloma. *Pathologie Biologie*, 38(8), 829.
- Avvisati, G., Petrucci, M. T., Pulsoni, A., Tribalto, M., Lauti, V. M., Gernone, A., ... Mandelli, F. (1990). Alpha-2b recombinant interferon (Intron-A) as maintenance treatment in multiple myeloma. *European Journal of Haematology*, 45(52 S), 9–11. <https://doi.org/10.1111/j.1600-0609.1990.tb00897.x>
- Massaia, M., Bianchi, A., Dianzani, U., Camponi, A., Attisano, C., Boccadoro, M., & Pileri, A. (1990). Defective interleukin-2 induction of lymphokine-activated killer (LAK) activity in peripheral blood T lymphocytes of patients with monoclonal gammopathies. *Clinical and Experimental Immunology*, 79(1), 100–104.
- Corradini, P., Palumbo, P., Battaglio, S., Ponzio, G., Boccadoro, M., & Pileri, A. (1990). Analysis of the breakpoint cluster region in essential thrombocythemia. *Haematologica*, 75(6), 573–575.
- Palumbo, A. P., Boccadoro, M., Battaglio, S., Corradini, P., Tschlis, P. N., Huebner, K., ... Croce, C. M. (1990). Human Homologue of Moloney Leukemia Virus Integration-4 Locus {MLV-4} Located 20 Kilobases 3' of the myc Gene, Is Rearranged in Multiple Myelomas. *Cancer Research*, 50(20), 6478–6482.
- Palumbo, A. P., Garino, A. L., Frieri, R., Gallone, G., Boccadoro, M., & Pileri, A. (1990). Consolidation treatment with dexamethasone and alpha-2B recombinant interferon further reduces the M-component level in multiple myeloma patients responding to conventional induction chemotherapy. *Haematologica*, 75(6), 576–578.
- Pileri, A., Tarella, C., Bregni, M., Boccadoro, M., Siena, S., Caracciolo, D., ... Gianni, A. M. (1990). GM-CSF-exposed peripheral blood progenitors as sole source of stem cells for autologous transplantation in two patients with multiple myeloma. *Haematologica*, 75(1 SUPPL.), 79–82.
- Boccadoro, M., Marmont, F., Tribalto, M., Fossati, G., Redoglia, V., Battaglio, S., ... Pileri, A. (1989). Early responder myeloma: Kinetic studies identify a patient subgroup characterized by very poor prognosis. *Journal of Clinical Oncology*, 7(1), 119–125. <https://doi.org/10.1200/JCO.1989.7.1.119>
- Palumbo, A. P., Boccadoro, M., Battaglio, S., Corradini, P., Giovinnazzo, B., Avanzi, G., & Ponzio, G. (1989). Philadelphia-positive thrombocythemia with a complex translocation involving chromosomes 9, 15, and 22. *Cancer Genetics and Cytogenetics*, 39(1), 77–80. [https://doi.org/10.1016/0165-4608\(89\)90232-X](https://doi.org/10.1016/0165-4608(89)90232-X)
- Pileri, A., Ferrero, D., Massaia, M., Dianzani, U., & Boccadoro, M. (1989). Advances in biology of multiple myeloma: Cell kinetics, molecular biology and immunology. *European Journal of Haematology*, 43(51 S), 30–34. <https://doi.org/10.1111/j.1600-0609.1989.tb01489.x>

- Palumbo, A. P., Pileri, A., Dianzani, U., Massaia, M., Boccadoro, M., & Calabretta, B. (1989). Altered Expression of Growth-regulated Protooncogenes in Human Malignant Plasma Cells. *Cancer Research*, 49(17), 4701–4704.
- Pegoraro, L., Malavasi, F., Bellone, G., Massaia, M., Boccadoro, M., Saglio, G., ... Avanzi, G. C. (1989). The human myeloma cell line LP-1: A versatile model in which to study early plasma-cell differentiation and c-myc activation. *Blood*, 73(4), 1020–1027.
- Boccadoro, M., Omede, P., Frieri, R., Battaglio, S., Gallone, G., Massaia, M., ... Pileri, A. (1989). Multiple myeloma: Beta-2-microglobulin is not a useful follow-up parameter. *Acta Haematologica*, 82(3), 122–125. <https://doi.org/10.1159/000205322>
- Pileri, A., Barbui, T., Boccadoro, M., Comotti, B., Dammacco, F., Gallamini, A., ... Mandelli, F. (1989). Cell kinetics and therapy in multiple myeloma: An uptake of the M83 protocol. *Bone Marrow Transplantation*, 4(SUPPL. 1), 168–169.
- Massaia, M., Dianzani, U., Bianchi, A., Camponi, A., Boccadoro, M., & Pileri, A. (1989). Immune dysregulation in monoclonal gammopathies. *Bone Marrow Transplantation*, 4(SUPPL. 1), 165–167.
- Boccadoro, M., Bianchi, A., Dianzani, U., Frieri, R., Gallone, G., Massaia, M., ... Pileri, A. (1989). Prognostic factors in multiple myeloma | FATTORI PROGNOSTICI NEL MIELOMA MULTIPLA. *Haematologica*, 74(5 SUPPL.), 347–357.
- Palumbo, A. P., Pileri, A., Battaglio, S., Omede, P., Redoglia, V., Massaia, M., ... Boccadoro, M. (1989). Monoclonal immunoglobulin gene rearrangement in peripheral lymphocytes of a patient with multiple myeloma. *Tumori*, 75(1), 1–3.
- Mandelli, F., Tribalto, M., Avvisati, G., Cantonetti, M., Petrucci, M. T., Boccadoro, M., ... Dammacco, F. (1988). Recombinant interferon alfa-2b (INTRON A) as post-induction therapy for responding multiple myeloma patients. M84 protocol. *Cancer Treatment Reviews*, 15(SUPPL. A), 43–48. [https://doi.org/10.1016/0305-7372\(88\)90073-4](https://doi.org/10.1016/0305-7372(88)90073-4)
- Massaia, M., Dianzani, U., Pioppo, P., Boccadoro, M., Redoglia, V., Omede, P., & Pileri, A. (1988). Emergence of activated lymphocytes in CD4 and CD8 subpopulations of multiple myeloma: correlation with the expansion of suppressor T-cells (CD8+ OKM1+) and ecto-5' nucleotidase deficiency. *Journal of Clinical and Laboratory Immunology*, 26(2), 89–95.
- Massaia, M., Pileri, A., Boccadoro, M., Bianchi, A., Palumbo, A., & Dianzani, U. (1988). The generation of alloreactive cytotoxic T lymphocytes requires the expression of ecto-5' nucleotidase activity. *Journal of Immunology*, 141(11), 3768–3775.
- Dianzani, U., Pileri, A., Boccadoro, M., Palumbo, A., Pioppo, P., Bianchi, A., ... Massaia, M. (1988). Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: Correlation with diagnosis and disease status. *Blood*, 72(3), 1064–1068.
- Massaia, M., Dianzani, U., Bianchi, A., Camponi, A., Boccadoro, M., & Pileri, A. (1988). Defective generation of alloreactive cytotoxic T lymphocytes (CTL) in human monoclonal gammopathies. *Clinical and Experimental Immunology*, 73(2), 214–218.
- Boccadoro, M., Omedé, P., Massaia, M., Dianzani, U., Pioppo, P., Battaglio, S., ... Pileri, A. (1988). Human myeloma: Several subsets of circulating lymphocytes express plasma cell-associated antigens. *European Journal of Haematology*, 40(4), 299–304. <https://doi.org/10.1111/j.1600-0609.1988.tb00181.x>
- Pileri, A., Massaia, M., Dianzani, U., Omedè, P., & Boccadoro, M. (1987). Cytobiological studies in multiple myeloma. *Acta Haematologica*, 78, 41–42. <https://doi.org/10.1159/000205901>
- Dianzani, U., Massaia, M., Pioppo, P., Boccadoro, M., Omede, P., & Pileri, A. (1987). Biochemical evidence for the presence of abnormal B lymphocytes in the peripheral blood of multiple myeloma patients. *The Alabama Journal of Medical Sciences*, 24(4), 400–404.
- Massaia, M., Dianzani, U., Pioppo, P., Sibilla, E., Boccadoro, M., & Pileri, A. (1987). Multiple myeloma: Ecto-5' nucleotidase deficiency of suppressor/cytotoxic (CD8) lymphocytes is a marker for the expansion of suppressor T cells. *Clinical and Experimental Immunology*, 69(2), 426–432.
- Boccadoro, M., Massaia, M., Dianzani, U., & Pileri, A. (1987). Multiple myeloma: biological and clinical significance of bone marrow plasma cell labelling index. *Haematologica*, 72(2), 171–175.
- Boccadoro, M., & Pileri, A. (1987). Cell kinetics of multiple myeloma. *Hematologic Pathology*, 1(3), 137–142.

- Boccadoro, M., Durieb, B. G., Frutigerb, Y., Gavarotti, P., Redogliaa, V., Massaia, M., ... Pileri, A. (1987). Lack of correlation between plasma cell thymidine labelling index and serum beta-2-microglobulin in monoclonal gammopathies. *Acta Haematologica*, 78(4), 239–242. <https://doi.org/10.1159/000205885>
- Gavarotti, P., Fortina, F., Costa, D., Verzetti, G., Redoglia, V., & Boccadoro, M. (1986). Benign monoclonal gammopathy presenting with severe renal failure. *Scandinavian Journal of Haematology*, 36(1), 115–117. <https://doi.org/10.1111/j.1600-0609.1986.tb02661.x>
- Boccadoro, M., Gavarotti, P., Ciaiolo, C., Golzio, F., Omedè, P., Redoglia, V., & Pileri, A. (1986). Cytokinetic studies in human myeloma. *Basic and Applied Histochemistry*, 30(2), 233–237.
- Boccadoro, M., Redoglia, V., Gavarotti, P., & Pileri, A. (1986). Multiple myeloma plasma cell kinetics: rapid and reliable evaluation using 5-bromo-2-deoxyuridine (BrdUrd) DNA incorporation detected by an anti-BrdUrd monoclonal antibody. *Tumori*, 72(2), 135–137.
- Tribalto, M., Amadori, S., Cantonetti, M., Franchi, A., Papa, G., Pileri, A., ... Mandelli, F. (1985). Treatment of multiple myeloma: A randomized study of three different regimens. *Leukemia Research*, 9(8), 1043–1049. [https://doi.org/10.1016/0145-2126\(85\)90075-X](https://doi.org/10.1016/0145-2126(85)90075-X)
- Gavarotti, P., Boccadoro, M., Redoglia, V., Golzio, F., & Pileri, A. (1985). Reactive plasmacytosis. Case report and review of the literature. *Acta Haematologica*, 73(2), 108–110. <https://doi.org/10.1159/000206293>
- Massaia, M., Ma, D. D. F., Boccadoro, M., Golzio, F., Gavarotti, P., Dianzani, U., & Pileri, A. (1985). Decreased ecto-5'nucleotidase activity of peripheral blood lymphocytes in human monoclonal gammopathies: Correlation with tumor cell kinetics. *Blood*, 65(3), 530–534.
- Boccadoro, M., Gallamini, A., Fruttero, A., Gavarotti, P., Redoglia, V., Buffa, F., ... Pileri, A. (1985). Plasma cell acid phosphatase activity as prognostic factor in multiple myeloma: Relationship to the thymidine-labeling index. *Journal of Clinical Oncology*, 3(11), 1503–1507. <https://doi.org/10.1200/JCO.1985.3.11.1503>
- Boccadoro, M., Gavarotti, P., Fossati, G., Pileri, A., Marmont, F., Neretto, G., ... Durie, B. G. M. (1984). Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy. *British Journal of Haematology*, 58(4), 689–696. <https://doi.org/10.1111/j.1365-2141.1984.tb06116.x>
- Boccadoro, M., Gavarotti, P., & Pileri, A. (1984). Monoclonal gammopathy of uncertain significance | Monoclonal gammopathy of uncertain significance. *Haematologica*, 69(6), 773–775.
- Carmagnola, A. L., Boccadoro, M., Massaia, M., & Pileri, A. (1983). The idiotypic specificities of lymphocytes in human monoclonal gammopathies: Analysis with the fluorescence activated cell sorter. *Clinical and Experimental Immunology*, 51(1), 173–177.
- Boccadoro, M., Gavarotti, P., Fossati, G., Massaia, M., Pileri, A., & Durie, B. G. (1983). Kinetics of circulating B lymphocytes in human myeloma. *Blood*, 61(4), 812–814.
- Carmagnola, A. L., Boccadoro, M., & Pileri, A. (1983). Mixed lymphocyte reaction in human monoclonal gammopathies. *Experientia*, 39(10), 1137–1139. <https://doi.org/10.1007/BF01943148>
- Pileri, A., Boccadoro, M., & Carmagnola, A. (1983). Immunological and kinetic features of human myeloma. *Journal of Experimental and Clinical Cancer Research*, 2(2), 225–227.
- Pileri, A., Carmagnola, A., & Boccadoro, M. (1982). Human myeloma: Kinetics of the remission phase. *Acta Haematologica*, 68(3), 237–240. <https://doi.org/10.1159/000206986>
- Boccadoro, M., Gavarotti, P., Massaia, M., & Pileri, A. (1982). Idiotypic study of human myeloma | Studi idiotipici nel mieloma umano. *Minerva Medica*, 73(18), 1175–1178.
- Boccadoro, M., Van Acker, A., Pileri, A., & Urbain, J. (1981). Idiotypic lymphocytes in human monoclonal gammopathies. *Annales de l'Institut Pasteur. Immunologie*, 132(1), 9–19. [https://doi.org/10.1016/0769-2625\(81\)90003-9](https://doi.org/10.1016/0769-2625(81)90003-9)
- Boccadoro, M., van Acker, A., Carmagnola, A., Conte, F., & Pileri, A. (1981). Monitoring of a long survival myeloma patient. *Tumori*, 67(6), 571–573.
- Pileri, A., Boccadoro, M., Mandelli, F., & Amadori, S. (1981). Growth kinetics of minimal tumour masses: Implications for rational chemotherapy. *Haematologica*, 66(5), 545–553.
- Conte, P. F., Boccadoro, M., & Pileri, A. (1980). Early B lymphocytes in man. *Experientia*, 36(9), 1124–1125. <https://doi.org/10.1007/BF01966008>

- Pileri, A., & Boccadoro, M. (1979). Kinetic and immunological studies in human myeloma: clinical implications (author's transl) | Indagini cinetiche e immunologiche nel mieloma umano: implicanze cliniche. *Haematologica*, 64 Suppl, 30–34.
- Pileri, A., Boccadoro, M., & Conte, P. F. (1979). Kinetic and immunologic considerations in the therapy of immunoproliferative disorders | CONSIDERAZIONI CINETICHE ED IMMUNOLOGICHE NELLA TERAPIA DEI DISORDINI IMMUNOPROLIFERATIVI. *Recenti Progressi in Medicina*, 66(2), 103–115.
- Hulin, N., Boccadoro, M., Masera, P., & Pileri, A. (1978). Biology of the human myeloma cell population. I. Macromolecular characteristics. *Ricerca in Clinica e in Laboratorio*, 8(1–2), 39–48.
- Pileri, A., Boccadoro, M., & Conte, P. F. (1977). Human myeloma | Il Mieloma Umano. *Annali Dell'Ospedale Maria Vittoria Di Torino*, 20(1–6), 10–15.
- Pileri, A., Conte, P. F., Boccadoro, M., & Hulin, N. (1977). Breakdown of RNA and protein synthesis template stability in proliferating and non proliferating human myeloma cells. *Haematologica*, 62(5), 559–561.
- Conte, P. F., Boccadoro, M., & Pileri, A. (1977). B lymphocytes receptors: a new biological approach for immunofluorescence studies. *Haematologica*, 62(2), 221–222.
- Katavama, I., Conte, P. F., Boccadoro, M., Pileri, A., Golde, D. W., Saxon, A., & Stevens, R. H. (1977). Hairy-Cell Leukemia. *New England Journal of Medicine*, 296(15), 881–882. <https://doi.org/10.1056/NEJM197704142961518>
- Pileri, A., Bernengo, M. G., Boccadoro, M., Conte, P., Marinone, C., & Masera, P. (1976). Early recruitment in the human myeloma cell population after cytostatic treatment. *Haematologica*, 61(2), 184–193.